

Experimental Eye Research

Progress in developing rodent models of age-related macular degeneration (AMD)

--Manuscript Draft--

Manuscript Number:	YEXER-D-20-00154R2
Article Type:	Review Article
Keywords:	Age-related macular degeneration, Animal models, Rodents, Oxidative stress, Hypoxia, Inflammation, Retina
Corresponding Author:	Jessica L Teeling, PhD University of Southampton Southampton, UNITED KINGDOM
First Author:	Sudha Priya Soundara Pandi, BSc, MSc, PhD
Order of Authors:	Sudha Priya Soundara Pandi, BSc, MSc, PhD J. Arjuna Ratnayaka, BSc, MPhil, DIC, PhD Andrew J Lotery, MD, FRCOphth Jessica L Teeling, PhD
Abstract:	Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss, typically affecting individuals from mid-life onwards. Its multifactorial aetiology and the lack of any effective treatments has spurred the development of animal models as research and drug discovery tools. Several rodent models have been developed which recapitulate key features of AMD to provide insights into its underlying pathology. These have contributed to making significant progress in understanding the disease and the identification of novel therapeutic targets. However, a major caveat with existing models is that they do not demonstrate the full disease spectrum. In this review, we outline advances in rodent AMD models from the last decade. These models feature various hallmarks associated with AMD, including oxidative stress, hypoxia, immune dysregulation, genetic mutations and environmental risk factors. The review summarizes the methods by which each model was created, its pathological characteristics as well as its relation to the disease in humans.
Suggested Reviewers:	Kai Kaarniranta, MD., PhD., MSc Professor (Full), Chief Physician, Head of Department, University of Eastern Finland kai.kaarniranta@uef.fi Expert in the Age-related macular degeneration. Roly Megaw, M.B.B.S, PhD Clinical Lecturer and Honorary Consultant, The University of Edinburgh roly.megaw@ed.ac.uk Expert in retinal disease Robert F Mullins, MS, PhD Martin Carver Chair in Ocular Cell Biology Professor of Ophthalmology and Visual, University of Iowa robert-mullins@uiowa.edu Expert in degenerative diseases of the retina Mariya Moosajee, MBBS BSc PhD FRCOphth Associate Professor, university college of london m.moosajee@ucl.ac.uk expert in retinal disease Brendan Kennedy Kennedy, BSc, PhD Professor, University College Dublin brendan.kennedy@ucd.ie expert in this field
Response to Reviewers:	

Progress in developing rodent models of age-related macular degeneration (AMD)

Sudha Priya Soundara Pandi¹, J. Arjuna Ratnayaka^{1*}, Andrew J Lotery^{1,2*}, Jessica L. Teeling^{3*}

¹Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, MP806, Tremona Road, Southampton, SO16 6YD, United Kingdom.

²Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, United Kingdom.

³Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, MP840, Tremona Road, Southampton, SO16 6YD, United Kingdom.

* Correspondence to Andrew Lotery a.j.lotery@soton.ac.uk, or Arjuna Ratnayaka J.Ratnayaka@soton.ac.uk or Jessica Teeling J.Teeling@soton.ac.uk

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss, typically affecting individuals from mid-life onwards. Its multifactorial aetiology and the lack of any effective treatments has spurred the development of animal models as research and drug discovery tools. Several rodent models have been developed which recapitulate key features of AMD and provide insights into its underlying pathology. These have contributed to making significant progress in understanding the disease and the identification of novel therapeutic targets. However, a major caveat with existing models is that they do not demonstrate the full disease spectrum. In this review, we outline advances in rodent AMD models from the last decade. These models feature various hallmarks associated with AMD, including oxidative stress, hypoxia, immune dysregulation, genetic mutations and environmental risk factors. The review summarises the methods by which each model was created, its pathological characteristics as well as its relation to the disease in humans.

Keywords: Age-related macular degeneration, Animal models, Rodents, Oxidative stress, Hypoxia, Inflammation, Retina.

1. Introduction

Age-related macular degeneration (AMD) is a sight-threatening disease that causes irreversible loss of central vision. AMD typically affects older individuals (>55 years) and is the most common cause of blindness amongst adults in developed countries (Colijn et al., 2017). AMD has a multifactorial aetiology (Nowak, 2006). Apart from age, various factors have been associated with increased risk, including blue light exposure (Taylor et al., 1990), smoking (Cackett et al., 2008; Mitchell et al., 2002), genetic predisposition (Abbas and Azzazy, 2013; Anastasopoulos et al., 2012; Rohrer et al., 2019), and diet (Robman et al., 2007) as well as comorbidities including cardiovascular disease (Chakravarthy et al., 2010). These factors advance the onset of age-related changes in the retina and may contribute to the earlier onset of the disease. The first changes, which can be visualised by fundoscopy, include the presence of yellow spots under the retina, called drusen, as well as hyperpigmentation of retinal pigment epithelium (RPE) in the macula. This phenotype is categorised as early AMD. The disease can progress to either advanced 'dry' AMD, also known as geographic atrophy (GA), or 'wet' AMD, which is referred to as neovascular AMD. Advanced dry AMD is characterised by atrophy of the photoreceptors and RPE in the macular region, while the presence of newly formed leaky/blood vessels typifies wet AMD associated with haemorrhage and ultimately scarring of the retina (Ehrlich et al., 2008; Fine et al., 2000; Hageman et al., 1995). Histopathologically, early AMD is characterised by the presence of soft drusen, loss of photoreceptor outer segments (POS), and RPE abnormalities including hypopigmentation/hyperplasia/hypertrophy and thickening of the Bruch's membrane (BM). Basal laminar deposits (BLamD) also form between the RPE basement membrane and its plasma membrane, whilst basal linear deposits (BLinD) form between the RPE basement membrane and the inner collagenous layer of the BM. Advanced wet AMD is characterised by the presence of drusen, pigment epithelium detachment and sub-RPE or sub-retinal haemorrhage. Terminal stages also feature the absence of POS and RPE in the lesion area, reduced outer nuclear layer (ONL) thickness, reduced choriocapillaris density, and gliosis. The inner nuclear layer (INL) has also been observed in close proximity to the BM and some patients may develop a disciform scar (Bird et al., 2014; Curcio et al., 1998; Green, 1999; Li et al., 2018; Sarks, 1976)

The daily intake of Age-Related Eye Disease Study (AREDS) recommended supplements, including vitamin C, E, lutein, zeaxanthin, zinc and copper which have been shown to delay the progression from early to advanced AMD (Age-Related Eye Disease Study Research, 2001; Hubschman et al., 2009; Moutray and Chakravarthy, 2011; Nowak, 2006). However, there are no disease-modifying treatments for advanced dry AMD. Inhibition of complement and inflammation showed promising effects in phase 2 clinical trials (Li et al., 2017; Zajac-Pytrus et al., 2015), but phase 3 clinical trials of complement inhibition (CHROMA and SPECTRI) failed to demonstrate any beneficial effects (Holz et al., 2018). Currently, antibodies targeting vascular endothelial growth factor (VEGF) are used to treat or manage, but not cure, wet AMD (Hubschman et al., 2009; Moutray and Chakravarthy, 2011; Nowak, 2006). The lack of disease-modifying therapies for early AMD and/or the GA phenotypes of advanced AMD may be partly due to an incomplete understanding of the complex biological processes underlying the disease.

In the past decade, a number of animal models have been developed that recapitulate salient features of AMD. Such models have the potential to enable proof-of-principle studies prior to clinical trials. Efforts to develop animal models which recapitulate the full disease spectrum have thus far failed. A major limitation in widely utilised rodent models is the absence of an anatomical macula, which is defined histologically as two or more layers of ganglion cells (Remington and Goodwin, 2011). Rodents also lack the fovea, a region in the centre of the macula in which only cone cells are present. The macula contains a mixture of rod and cone photoreceptors but is dominated by the former cell-type (Osterberg, 1935). It is increasingly evident that AMD exhibits a multifactorial aetiology, with influences including oxidative stress, hypoxia, inflammation and angiogenesis driven by a combination of genetic and environmental risk factors. Animal models that incorporate multiple factors may therefore be more relevant to studying AMD. To date, models including zebrafish, pigs and non-human primates have been used to study AMD, however rodent models are preferred due to their ease of breeding/handling, rapid onset of disease and relatively low-cost. A review which summarised some of these models was published in 2012 (Pennesi et al., 2012). However, several new models have since been described. In this review, we provide an updated and comprehensive description of recent rodent models developed to investigate AMD and discuss their potential use for translational as well as drug discovery

studies. The described rodent models have been broadly grouped based on disease pathways, associated AMD-like features, the means by which pathology was induced, or a combination thereof.

2. Models of oxidative stress

The POS containing polyunsaturated fatty acids are prone to cellular damage, forming lipid peroxides following exposure to light (Figure 1) (Winkler et al., 1999). The young retina can regulate oxidative stress and prevent damage due to the presence of natural antioxidants (e.g. lutein and zeaxanthin) and antioxidant enzymes such as superoxide dismutase (SOD), catalase and metallothionein (Yildirim et al., 2011). With ageing, these natural protective mechanisms become less effective or are lost, resulting in lipid oxidation, oxidative stress and damage to POS (Beatty et al., 2000). The phagocytic and proteolytic activities of the RPE are also impaired with age, resulting in the accumulation of intracellular lipofuscin and formation of sub-RPE drusen (Figure 1). Moreover, lipoprotein accumulation contributes to oxidative stress in choroidal endothelial cells, leading to elevated reactive oxygen and nitrogen species associated with inflammation and tissue damage (Feeney-Burns et al., 1984; Okubo et al., 1999; Ryan et al., 2012; Sundelin et al., 1998; Zarbin, 2004). These disease features are well-characterised in AMD patients, allowing investigators to develop animal models targeting a single antioxidant system or the nuclear factor responsible for the expression of a number of antioxidants (see table 1).

2.1. Conditional induction of oxidative stress in mice

Superoxide dismutase is an enzyme that acts as an antioxidant to break down reactive oxygen molecules in the cell. Mice deficient in SOD1 (SOD1^{-/-}) (Imamura et al., 2006) or SOD2 (SOD2^{-/-}) (Justilien et al., 2007) mimic age-related loss of these enzymes. Early SOD2^{-/-} mouse models were generated by the sub-retinal injection of an adenovirus expressing ribozyme. This decreases the enzyme manganese superoxide dismutase (MnSOD), which in turn triggers oxidative stress in RPE cells. SOD2^{-/-} mice show features of early AMD including BLamD, BM thickening, and increased presence of lipofuscin and vacuolisation in RPE cells, which eventually leads to RPE atrophy. A limitation of this model is the variability in the

amount of adenovirus plasmid delivered by sub-retinal injection. The pathology observed in *SOD2^{-/-}* mice may also be due to inflammation caused by sub-retinal injection-induced retinal detachment. Furthermore, knockout of *SOD2* was not sufficient to replicate the progression from the early stages to advanced AMD (Justilien et al., 2007). To refine this model, the RPE monolayer was directly targeted using the cre-lox system (Biswal et al., 2016; Mao et al., 2014). The resulting conditional knockout of *Sod2* was induced by feeding *Sod2^{flox/flox}*VMD2-cre mice with doxycycline (dox). Knockout of *Sod2* was confirmed by evidence of reduced MnSOD expression in the RPE, which was not observed in the absence of dox. After 6 weeks, the RPE showed increased 8-hydroxy-2'-deoxyguanosine (8-OHdG) immunoreactivity. 8-OHdG is the predominant free radical produced by the oxidation of DNA, and its accumulation in the cell acts as a marker for measuring oxidative stress. Hence, it is used to detect oxidative stress in the RPE. Fundus images of 6 and 9 month old *Sod2^{flox/flox}*VMD2-cre mice on dox showed a white reflective area indicating retinal thinning. Spectral domain-optical coherence tomography (SD-OCT) images revealed 15% and 24% reduction in the ONL thickness and increased choroidal porosity at 6 and 9 months respectively, which indicate degeneration in photoreceptor and choroid tissues. The atrophic area observed by fundoscopy showed vascular leakage and retinal blood vessel abnormalities in fluorescein angiography (FA). Functional measurements by ERG showed a significant reduction of scotopic (dark-adapted) alpha (A) and beta (B) waves and photopic (light-adapted) B waves at 6 and 9 months, confirming reduced photoreceptor function in the atrophic retina. In contrast, A and B waves of the *Sod2^{flox/flox}*VMD2-cre mice without dox were similar to wild type (WT) control mice. Clinical symptoms of hypopigmented spots in the fundus, ONL thinning and reduced photoreceptor function is an indication of atrophy. BLam- like deposits were observed between the RPE and the BM by histology. The thickness of the RPE at 9 months was increased by 30% and EM revealed vacuolated RPE cells, and the photoreceptor inner segment (PIS) and POS located above vacuolated RPE were found to be shortened. No such pathogenic changes were observed in mice without dox. Using confocal imaging to measure autofluorescence revealed a 20-fold increase in retinal fluorescence intensity of 4 month old *Sod2^{flox/flox}*VMD2-cre animals compared to WT mice. The investigators did not observe any evidence of choroidal neovascularisation (CNV) in these mice. Thus, this conditional mouse model mimics the dry form of AMD. Nonetheless, it is

worth noting that both OCT and histological analyses do not show true atrophic pathology in the retinal cross-section, which suggests that the hypopigmented area seen in the fundus might not be an atrophic phenotype as seen in patients.

2.2. *Nrf2*^{-/-} mice

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a negative regulator of oxidative stress. It is a transcription factor that binds to the antioxidant responsive element located upstream of genes encoding detoxifying enzymes [glutathione S-transferase (GST) and NAD(P)H:quinone oxidoreductase 1 (NQO1)] or antioxidant enzymes (glutathione and SOD) (Venugopal and Jaiswal, 1998). Hence, deletion of Nrf2 might lead to uncontrolled oxidative stress as seen in early AMD. An Nrf2 knockout (*Nrf2*^{-/-}) model was created by deletion of exon 4 and 5 in *Nfe2l2* gene. Examination of mouse eyes using fundoscopy showed well-defined drusen-like deposits at 8-11 months (Zhao et al., 2011). By 11-18 months of age, these mice develop larger soft drusen-like deposits with ill-defined margins in the mid-peripheral retina, similar to those observed in human fundus images of early AMD patients. In 18% of *Nrf2*^{-/-} mice, spontaneous CNV develops between 11-17 months, characteristic of wet AMD. Functional measurements of the retina at 12 months show compromised retinal function, which was confirmed by reduced A and B waves compared to age-matched WT controls. Histologically, a continuous basal deposit underneath the RPE was observed in *Nrf2*^{-/-} mice at 11 months. At 12 months, an increased vacuolisation of the RPE was seen, with increased autofluorescence. The RPE was also hyperpigmented near the vacuolated region and hypopigmented in non-vacuolated areas. Some areas showed RPE atrophy, especially above the BLam-like deposits in 12 month old *Nrf2*^{-/-} mice. Compromised autophagy as a consequence of dysfunctional lysosomes was found in electron microscopy (EM) images at 12 months. Thickening of the BM, loss of choroidal fenestration, a thickened choriocapillaris endothelium and infiltrating cells in the sub-RPE region are all observed in 12 month old *Nrf2*^{-/-} mice. CNV was confirmed in 12 month old *Nrf2*^{-/-} animals by the presence of new choroidal vessels, breaks in the choriocapillaris endothelial processes, and BM abnormalities. Other observed pathologies include the presence of haemorrhages and exudates in the sub-RPE region, RPE hyperplasia and POS atrophy. Evidence of immune dysregulation includes increased levels of complement factor C3d, serum amyloid P,

vitronectin and IgG in the RPE/BM junction (Zhao et al., 2011). This model, therefore, shows features of both dry and wet AMD, phenotypes which are commonly seen in patients (Wang et al., 1998). The limitation of this model is the presence of only a few mid-peripheral drusen-like deposits, which might suggest that they are not true drusen as seen in AMD patients. A high-fat diet can increase the risk of developing AMD (Cho et al., 2001). Interestingly, *Nrf2*^{-/-} mice fed a high fat diet (HFD) show advanced RPE hyper/hypopigmentation and hyperplasia with a ~2 fold increase in autofluorescence as well as sub-retinal drusen-like deposits at 16 months. CNV was observed in 15% of *Nrf2*^{-/-} mice with the presence of infiltrating macrophages and an increased number of sub-retinal microglia compared to WT fed a HFD. No pathology was detected in WT fed normal chow (Zhao et al., 2014).

2.3. *PPARβ/δ*^{-/-} mice

Peroxisome proliferator-activated receptor beta/delta (*PPARβ/δ*) is one of the nuclear receptor superfamilies, which also acts as a ligand-activated transcription factor. It regulates various signalling pathways related to AMD, including glucose and lipid metabolism, fatty acid oxidation, extracellular matrix (ECM) turnover, inflammation, apoptosis, proliferation, cell differentiation and angiogenesis (Bishop-Bailey, 2008; Bishop-Bailey and Bystrom, 2009; Malek, 2014). *PPARβ/δ* is expressed and can be activated in the RPE and choroid (Choudhary et al., 2016). The role of this receptor in the retina has been studied in *PPARβ/δ*^{-/-} mice developed by Choudhary et al., 2016, which show features of an early AMD-like phenotypes. At 18 months, these mice show RPE hypo/hyperpigmentation, damaged basal infolding, increased autofluorescence, a thickened BM, continuous sub-RPE deposits with increased apolipoprotein E (ApoE) expression in BM and sub-RPE deposits, suggesting a protective role of *PPARβ/δ* in the ageing retina, possibly by regulating lipid metabolism. Interestingly, *PPARβ/δ*^{-/-} mice exhibit reduced injury following laser-induced CNV, and similar observations were made using the *PPARβ/δ* antagonist GSK0660. These studies imply that selective targeting of *PPARβ/δ* may be a suitable strategy for the treatment of different clinical sub-types of AMD, for example using receptor agonists for treating dry AMD and antagonistic treatments for wet AMD. The *PPARβ/δ*^{-/-} model encompasses some features of early AMD and also acts as a platform to target CNV. However, these animals failed to show

any evidence of retinal abnormalities, or loss of choroidal fenestrations, which are important features of early AMD.

2.4. *PGC-1 α ^{+/-} mice*

Peroxisome proliferator-activated receptor gamma coactivator -1 alpha (PGC-1 α) is highly expressed in the INL (Guo et al., 2014). This receptor plays a crucial role in the regulation of angiogenesis, oxidative stress, mitochondrial biogenesis, autophagy and retinal and RPE senescence (Iacovelli et al., 2016; Kaarniranta et al., 2018; Saint-Geniez et al., 2013; Satish et al., 2018) and altered function of PGC-1 α might contribute to AMD pathology. Indeed, PGC-1 α ^{+/-} mice develop early AMD-like pathology, when exposed to a HFD (Zhang et al., 2018). Adult PGC-1 α ^{+/-} mice fed on a HFD for 4 months show PIS/POS thinning in one eye with the contralateral eye unaffected, which is often observed in AMD patients. EM analysis of RPE shows pronounced lipofuscin granule accumulation, collagenous layer thickening, BLamD as well as a loss of choroidal fenestrations, whilst these changes were not observed in WT control mice fed the same HFD diet. PGC-1 α ^{+/-} mice also possess a thickened or atrophic BM, degenerated RPE with loss of melanosome, and a thinned photoreceptor layer without infiltrating cells. Migration of RPE to the POS layer and presence of carboxymethyl lysine (a component of drusen) in the thickened BM were also noted along with a decrease in autophagy. Increased expression of *Vegfa* was also found in the retina/RPE of PGC-1 α ^{+/-} mice fed a HFD compared to WT controls on the same diet. Furthermore, PGC-1 α ^{+/-} mice show increased levels of drusen proteins ApoE, ApoJ, amyloid precursor protein (APP) expression, ROS, a decrease in SOD2 levels, mitochondrial DNA copy number and mitochondrial complex I activity. Thus, the dysregulated lipid metabolism, dysfunctional autophagy and oxidative stress in PGC-1 α ^{+/-} mice may be responsible for the AMD-like pathology in this mouse model, although functioning of the photoreceptors has not been evaluated in these mice.

2.5. *PGC-1 α /Nrf2 double knockout (dko) mice*

Mice lacking expression of both Nrf2 and PGC-1 α develop early AMD-like pathology at 12 months of age. Functional ERG measurement of Nrf2/PGC-1 α double knockout (dko) mice showed a decrease in A and B waves, implying impaired photoreceptor function. Nrf2/PGC-

1 α dko mice show more pronounced autophagy and oxidative stress compared to single knockout mice. TEM analysis of RPE in 12 month old dko mice showed vacuolated cells with numerous autolysosomes, damaged mitochondria with lost basal infolding, increased melanosomes and lipofuscin, a thickened BM, focal photoreceptor damage as well as the presence of electron-dense deposits compared to WT control mice. Histologically, 12 month old dko mice showed ONL thinning, altered BM structure and drusen-like deposits, and RPE cells showed evidence of hypertrophy and degeneration. Accumulation of Iba⁺ cells in the RPE flatmount of 12 month old dko mice confirms an inflammatory response to retinal damage (Felszeghy et al., 2019). Mitochondria also accumulate within autophagosomes of RPE cells, and increased autofluorescence and early endosomes further confirm dysregulated mitophagy and autophagy in dko mice, which could explain the AMD-like pathology observed in these animals (Sridevi Gurubaran et al., 2020). Choroidal abnormalities were not evaluated in this model.

2.6. *Cryba1* cko mice

Cryba1 is a gene that encodes the crystalline lens proteins β A1 and β A2, but the gene is also expressed in retinal astrocytes and RPE cells, where it plays a role in lysosomal activity (Sinha et al., 2012; Zigler and Sinha, 2015; Zigler et al., 2011). The conditional knockout (cko) of the *cryba1* gene was created by Valapala et al., 2014b using the cre-lox system. Fundus images of these cko mice showed late dry AMD pathology with the evidence of hypo/hyperpigmentation and sub-retinal lesions at the posterior pole at 4 months, and by 12 months these lesions had progressed. A decrease in A and B waves in ERG traces indicates a loss of photoreceptor function in 7 month old *Cryba1* cko mice. RPE flatmounts from 7 month old *Cryba1* cko mice show a disturbed cellular architecture with a loss of tight junctions. TEM analysis of 2 month old cko mice shows evidence of vacuolated RPE, membranous organelles with undigested POS and loss of basal infolding. With age (9 months), *Cryba1* cko mice display large vacuoles, partially degraded POS with increased melanosomes, autophagosomes and decreased type 1 lysosomes compared to *Cryba1*^{fl/fl} mice, indicating impaired lysosomal function and degeneration of the RPE. Histologically, lipid accumulation was predominantly observed in the RPE of 12 month old animals. *Cryba1* cko mice also show increased inflammation with increased expression of glial fibrillary

acidic protein (GFAP), increased numbers of Iba1⁺ cells in retinal flatmounts and increased CCL2 mRNA and protein expression in RPE (Valapala et al., 2014a; Valapala et al., 2014b). However, this model does not show evidence of other AMD features, including BM thickening, ONL thinning or choroidal pathology.

2.7. Mice with a high glycaemic (HG) diet

A high glycaemic (HG) diet is known to induce oxidative stress in the retina, which increases the risk of developing AMD (Cho et al., 2001; Mares-Perlman et al., 1995). Indeed, 12 month old C57BL/6 mice fed a HG diet for 12 months show loss of photoreceptors with progressive thinning of the ONL. The retina shows additional features of degeneration, including inner retinal thinning, photoreceptor disorganisation, IS swelling and loss of synapses in the outer plexiform layer (OPL). The HG diet also induces changes to RPE cells, including vacuolisation, hypopigmentation, disorganisation, thinning and increased sub-retinal deposits. The RPE cells adjacent to degenerated photoreceptors were multi-layered and atrophic, with increased phagosomes, lipofuscin granules and autofluorescence. These changes are not observed in mice on a control diet. Advanced glycation end products, as a biomarker of AMD, were highly expressed in the plasma and retina of mice fed a HG diet, and accumulation of oxidative and lipid peroxidised products was evident in the retina and RPE of HG fed mice, but not in the retina of mice on a control diet. HG diet also changed the gut microbiota, which was confirmed by metabolomics analysis. A HG diet promotes an unclassified gut microbiota profile, whereas a low glycaemic (LG) diet enriches for *Bacteroidales* and *Erysipelotrichi*, which may confer protection against AMD (Rowan et al., 2017). A HG diet appears to promote an early AMD phenotype, but this detrimental effect can be reversed by switching to a LG diet. Further analyses including functional measurements of photoreceptor activity, funduscopy and OCT scans remain to be carried out.

3. Models of retinal hypoxia

Hypoxia plays a key role in AMD (Arjamaa et al., 2009). In the healthy eye, both the inner and outer retina receive oxygen from retinal endothelial cells and choroidal endothelial

cells, respectively (Wangsa-Wirawan and Linsenmeier, 2003). The age-dependent thickening of the BM, increased distance to the retina due to drusen, choroidal thinning and low choroidal blood flow, impede the transport of nutrients and oxygen from the choroid to the outer retina (Figure 1) (Caprara and Grimm, 2012; Linsenmeier and Padnick-Silver, 2000). With increasing age, the decreased oxygen content in the outer retina might lead to ischemia. On the other hand, elevated retinal hypoxia stimulates the production of VEGF, which promotes the formation of new blood vessels (Stefansson et al., 2011). Hypoxia is mediated through transcription factors known as hypoxia inducible factors (HIFs). Among the HIFs, hypoxia-inducible factor 1 α (HIF-1 α) plays a crucial role in hypoxic conditions of most cell types. Under normal conditions, HIF-1 α undergoes oxidation via hydrolase enzyme (prolyl hydroxylase). However, under hypoxic conditions, this process is bypassed leading to the accumulation of HIF-1 α linked with increased VEGF synthesis and CNV (Arjamaa et al., 2009). The importance of HIF in neovascularisation was confirmed in AMD donor eyes which showed HIF-1 α and HIF-2 α positivity associated with the CNV membrane (Sheridan et al., 2009).

3.1. *P4h-tm*^{-/-} mice

Transmembrane Prolyl 4-hydroxylase (P4h-tm) is the regulator of HIF-1 α (Koivunen et al., 2007; Oehme et al., 2002). P4h-tm is highly expressed in the brain and eye, and most notably in RPE, as demonstrated by real-time PCR (Leinonen et al., 2016). Investigators manipulated HIF-1 α signalling by knocking out its regulator P4h-tm to create an AMD phenotype in mice. Functionally, P4h-tm^{-/-} mice showed normal rod and reduced cone function at 5-7 months. However, by 12-13 months, animals developed compromised rod function but with no functional defects in cones (Leinonen et al., 2016). Histologically, at 10 months the RPE of P4h-tm^{-/-} mice showed evidence of disorganisation, broadened intercellular spaces, basal infolding, BLamD as well as drusen-like sub-RPE debris. At 14.5 months, the RPE underwent significant thinning compared to age-matched WT mice. Furthermore, a change in the ONL thickness and a reduction in the length of the PIS and POS were detected. Both the ONL and POS displayed infolds, suggesting defects in the outer limiting membrane (Stuck et al., 2012). Retinal pathology progressed into old age. For instance, by 29 months, mice showed larger vacuoles as a consequence of enlarged

intercellular spaces between RPE cells as well as continuous BLam- drusen-like deposits in the sub-RPE space. EM micrographs displayed RPE with larger phagosomes in the apical region, indicating compromised phagocytosis. Thus, P4h-tm^{-/-} mice represent features of early AMD but do not show BM thickening or choroidal pathology, suggesting that hypoxia alone is not sufficient to promote AMD-like pathology.

4. Models of retinal inflammation

Studies indicate a significant association of inflammation with the onset and progression of AMD. Complement activation is one of the well-known inflammatory mechanisms linked to AMD (Patel and Chan, 2008; Whitcup et al., 2013). Single nucleotide polymorphisms (SNPs) in complement factors of the alternative complement pathway show the strongest association with AMD. The SNP Y402H (rs1061170) of complement factor H (CFH) was the first significant variant associated with AMD (Haines et al., 2005), resulting in exaggerated activation and deposition of complement in the retina (Edwards et al., 2005; Hageman et al., 2005; Klein et al., 1998; Klein et al., 2005). Other complement regulators include CD46 and CD59, the expression of which are decreased in monocytes of wet AMD patients (Singh et al., 2012). Diminished CD46 and CD59 expressions were also seen in the RPE during early AMD, and further decreased in atrophic AMD, implying that complement deposition may be due to the lack of negative regulation (Ebrahimi et al., 2013). Analysis of drusen proteomics demonstrates the presence of C-reactive protein, C3a, C5a, C5b-9, amyloid beta protein, vitronectin and alpha-1 antitrypsin (Donoso et al., 2006; Mullins et al., 2000; Nozaki et al., 2006; Wang et al., 2010), which confirms the link between inflammation and AMD. In AMD patients, retinal microglia also become reactive in response to RPE degeneration (Gupta et al., 2003). Various cytokines and chemokines, such as CCL2, CCL5, CCR2 and CX3CR1, which are secreted by RPE cells and macrophages, are also involved in the activation and recruitment of microglia to the sub-retinal space (Chen et al., 2008; Ma et al., 2012; Xu et al., 2009), that in turn may trigger CNV (Ma et al., 2012). Similarly, macrophages from the choroid might enter the sub-retinal space following degeneration of the RPE/BM (Figure 1) (Chen and Xu, 2015). Several rodent knock-in and knock-out models have been developed that recapitulate features of immune dysregulation including components of the alternative

complement pathway. Examples include, CFH^{-/-} mice (Coffey et al., 2007), CFH Y402H transgenic mice (Ufret-Vincenty et al., 2010), C3 overexpressing mice and C3a and C5a receptor knockout mice (Nozaki et al., 2006). Targeting regulators of the complement pathway, such as CD46, and/or inflammatory factors, such as cytokines/chemokines or microglia/macrophages may create more accurate models of AMD, some of which are summarised below (see table 1). Additionally, combining genetic models of AMD with environmental risk factors that influence the immune system, such as infection and/or diet, may lead to optimized models that mimic human AMD phenotypes more precisely.

4.1. Complement factor H (CFH) transgenic mice

CFH is a complement regulatory protein involved in the alternative pathway, which is strongly associated with AMD (Haines et al., 2005; Klein et al., 2005). The Y402H SNP affects binding of CFH to C-reactive protein and heparan sulfate, leading to chronic inflammation and increased lipoprotein accumulation in BM and sub-RPE deposits (Clark et al., 2010; Laine et al., 2007). This inflammatory response may be enhanced by age and/or environmental factors that induce lipid peroxidation in the retina, such as a high fat diet. To explore the combined effect of diet and AMD associated polymorphisms in CFH, Landowski et al., 2019 developed a transgenic mouse model by inserting the full length of the normal human CFH Y402 gene (CFH-Y/O), or the AMD associated CFH H402 variant gene, into CFH^{-/-} mice. Homozygous (CFH-H/H) mice were generated by inbreeding, and all mice were given a high fat, cholesterol diet (HFC) or control diet for 8 weeks. The levels of CFH, factor B (FB), and C3 in plasma and in the posterior of the eye were similar in all mice, irrespective of the type of diet. Aged CFH-H/H mice (90 week old) showed impaired photoreceptor function, as evidenced by a decrease in A and B waves in ERG measurements, which was dominated by rods (Bmax1) and not observed in age-matched mice on a normal diet. In addition, multinucleated RPE with larger BLamD could be observed in aged CFH-H/H mice fed a HFC diet, suggesting early pathological signs, reminiscent of human AMD. The pathological changes to the retina were not observed in younger (36-40 weeks) CFH-H/H mice or CFH-H/H mice fed a control diet, suggesting an interaction between age, diet and CFH polymorphisms. Only the eyes from aged mice carrying the AMD variant of CFH (Y402H/H) showed an increase in ApoB48 and ApoA1 levels following a HFC, suggesting that the

dysregulation of lipid metabolism and increased lipid accumulation may be responsible for the observed effects (Landowski et al., 2019). There was no evidence of BM thickening, retinal or choroidal changes reported in this model.

4.2. CFH^{-/-} with a glycaemic diet and CFH^{+/-} mice with a high fat, cholesterol (HFC) diet

Previously developed CFH^{-/-} mice by Coffey et al., 2007 only demonstrated few features of AMD including autofluorescence, disorganised POS, compromised photoreceptor function and BM thinning (Coffey et al., 2007). To refine this model, the deletion of CFH was combined with a HG diet. Histologically, no anatomical changes were evident in the retina of 44 week old CFH^{-/-} or C57BL/6J WT mice when placed on either HG and LG diet. Interestingly, CFH^{-/-} mice given a LG diet showed an increase in the number and distribution of vacuoles in the RPE layer. This was confirmed by EM analysis which showed that RPE cells were highly vacuolated and disorganised with disrupted basal infolding. These changes were accompanied by increased lipofuscin, accumulation of BLamD and infiltrating cells. Furthermore, autophagosomes in the basal infolding of RPE cells were recorded. A thickened BM was only observed in 50 week old mice. Overall, the low glycaemic diet seems to induce an early AMD-like pathology in CFH^{-/-} (Rowan et al., 2014). OCT and retinal function measurements were not studied in these mice. There is also no report of any choroidal pathology.

Another study compared heterozygous CFH^{+/-} mice and homozygous CFH^{-/-} mice and the combined effect of a high fat cholesterol diet (HFC). ERG measurement of CFH^{+/-} mice fed on a HFC diet shows reduced function of photoreceptors. CFH^{+/-} mice fed a HFC also show a 40% and 22% reduction in rod dominant (Bmax1) and cone dominant (Bmax2) response, respectively. Though the ultrastructure of RPE showed larger BLamD in CFH^{+/-} and CFH^{-/-} mice fed a HFC diet compared to WT control mice, RPE flatmounts showed increased numbers of multinucleated cells only in the CFH^{+/-} mice fed a HFC diet. Histological analysis showed a reduced ONL and thinned RPE only in CFH^{+/-} mice fed a HFC diet. Accelerated complement activation and corresponding chronic inflammation was confirmed by increased levels of C3a and C5a in the plasma of CFH^{+/-} mice fed a HFC diet and linked to increased immunoreactivity of CD11b⁺ in RPE/choroid. Flow cytometry analysis of RPE/choroid showed increased CD64⁺ cells with 12.8% of classical vs. 9.8% non-classical

monocyte populations in the CFH^{+/-} mice fed a HFC diet (Toomey et al., 2015). Altogether, CFH^{+/-} mice fed a HFC diet show features of early AMD but fail to demonstrate BM thickening and choroidal pathology.

4.3. CD46^{-/-} mice

CD46 inhibits the alternative complement pathway by acting as a cofactor for factor I to degrade C3b and C4b (Liszewski et al., 2005; Liszewski et al., 2000). CD46 is ubiquitously expressed in humans, but its expression is restricted to the retina and testis in mice (Holers et al., 1992). The presence of CD46 in the mouse retina, RPE and choroid suggests that manipulation of this gene might have the same effect as deleting CFH (Lyzogubov et al., 2014a), as both are involved in the degradation of C3b. At 12 months, CD46^{-/-} mice display increased levels of C5b-9 in the RPE/choroid compared to WT controls, suggesting an accelerated alternative pathway in the retina (Lyzogubov et al., 2016). A phenotype resembling dry AMD was observed in CD46^{-/-} mice at 12 months of age. Histological evaluation demonstrated hypertrophic, multinucleated and vacuolated RPE, implying degeneration of this monolayer. The presence of increased autophagosomes in 12 month old CD46^{-/-} mice indicated the activation of autophagy as a result of RPE degeneration. Fluorescent excitation of the RPE using 405nm, 488nm and 561nm wavelengths displayed increased autofluorescence. This data was supported by electron micrographs which revealed the accumulation of lipofuscin in the RPE cytoplasm as well as the deposition of electron-dense material between the BM and the RPE, coinciding with a thickened BM. Choroidal thinning, with reduced choriocapillary lumen and fenestrations and an increased presence of macrophage-like cells in the sub-retinal space, were also evident in 12 month old CD46^{-/-} mice. Apoptosis of photoreceptors was identified by the reduced density of the nucleus, but with unaltered ONL thickness. Consequently, the diminished number of nuclei in the ONL is likely due to rod photoreceptor shortening or cell death, which was confirmed by probing for rhodopsin protein expression, found to be reduced in 12 month old CD46^{-/-} mice. Low levels of VEGF isoforms (43 and 18KD) in the retinal/RPE/choroid of transgenic mice of a similar age confirmed that there was no evidence of neovascularisation (Lyzogubov et al., 2016). This model therefore demonstrates features of early, dry AMD at

retinal, RPE, BM and choroidal levels. However, anatomical changes and functional measurements such as funduscopy, OCT and ERG were not assessed in this model.

4.4. Inflammasome mice

Studies in GA eyes revealed reduced expression of Dicer1 (microRNA processing RNase), whose knockdown in human RPE cells causes the accumulation of Alu RNA and RPE degeneration (Kaneko et al., 2011). The exact role of Alu RNA on GA is unclear. However, canonical inflammasome proteins including NLRP3, pro-Casp1, Pycard, and p-IRAK1, as well as non-canonical proteins such as caspase-4, gasdermin D, IFN- β and cGAS, are increased in donor GA eyes compared to healthy age-matched controls. This suggests the role of inflammasome activation in AMD. To prove this mechanism, a study (Tarallo et al., 2012, Kaneko et al., 2011)) investigated TLR3, TLR7, MyD88 and inflammasome-related gene knockout mice. Sub-retinal delivery of Alu RNA into the TLR3, 7 and 9, and Dicer 1 deficient mice led to RPE degeneration. The fundus of these animals showed GA-like lesions, with a disturbed cobblestone morphology of RPE cells in flatmounts. However, Alu RNA receiving MyD88, NLRP3, Casp1/Casp11, Pycard, Cybb, Gsdmd, Infrar, Irf3, stat2, Tmem, as well as ppif knockout mice failed to show any evidence of RPE degeneration. These findings suggest that Alu RNA is activated through both canonical and non-canonical inflammasome pathways to induce RPE degeneration. The pathogenic effects of Alu RNA were rescued by Casp1 and MyD88 inhibition, as well as IL-1 β and IFN β overexpression in WT mice, suggesting these may be targets for future GA treatments.

4.5. P2X7 null mice

The P2X7 receptor belongs to the purinogenic receptor family and is a ligand-gated ion channel, which is activated by its native ligand, ATP. In some cases, P2X7 also acts as a scavenger receptor, the activation of which promotes phagocytosis of apoptotic cells and debris. This receptor acquires its scavenger function only in the absence of ATP (Wiley and Gu, 2012), and is expressed on microglial cells and macrophages (Monif et al., 2010). A failure in the function of this receptor might have a role in the accumulation of unprocessed material observed as drusen in AMD patients. The role of the P2X7 receptor has been studied in Caucasian populations with advanced AMD. The rare haplotype of P2X4 Tyr315cys, along with P2X7 150Arg, represented 4-fold increase in AMD patients compared

to healthy, age-matched controls (Gu et al., 2013). Furthermore, immunohistochemistry studies in macaque eyes confirmed P2X4 and P2X7-positive microglial cells in the inner plexiform layer, as well as P2X4 and P2X7-positive infiltrated macrophages from the choroid in the vicinity of drusen. This suggests an association between P2X7 and AMD (Gu et al., 2013). Vessey et al. 2017 developed a P2X7 null mouse model which demonstrates an early, dry AMD phenotype from 12 to 18 months. Examination of 18 month old P2X7 null mice by funduscopy showed elevated whitish lesions compared to WT littermates. Functional measurements by ERGs revealed a reduced scotopic rod photoreceptor response amplitude as well as a subtle reduction in the cone post photoreceptor timing in 18 month old P2X7 null mice, confirming impaired photoreceptor function. Analysis of RPE flatmounts from 18 month old P2X7 null mice showed hypertrophic, vacuolated and multinucleated RPE in the peripheral and central retina compared to WT controls. Ultrastructural studies revealed a pronounced thickening of the BM, BLam and BLin-like deposits, as well as electron-lucent deposits, in 12 month old P2X7 null mice, with BM thickening persisting up to 18 months. Histological studies at 12 months reported increased autofluorescence in RPE, but retinal thickness was unchanged at 12 and 18 months despite increased gliosis. Histopathology thus confirmed early signs of disease, including BLam-like and drusen-like deposits, with BM thickening and RPE degeneration similar to that seen in AMD pathology. Furthermore, flow cytometry showed that blood-borne macrophages in 4 and 12 month old P2x7 null mice exhibited a progressive reduction in phagocytosis compared to age-matched WT controls. Reduced phagocytosis was also observed in retinal microglia of 4, 12 and 18 month old P2X7 null mice compared to WT controls, alongside increased macrophages in POS, with C3 and C5 deposits in the sub-RPE region (Vessey et al., 2017). This model did not identify any changes in the retinal structure (ONL and photoreceptor) or the choroidal vasculature.

4.6. Polyethylene glycol (PEG)-induced retinal degeneration mouse model

PEG, in the form of phospholipid methoxy PEG, has been shown to modulate both the classical and alternative complement pathways (Moein Moghimi et al., 2006). Lyzogubov V. V. et al. (2014b) created a modified PEG-induced model of early dry AMD, in which a sub-retinal injection of 0.5 mg PEG promoted RPE atrophy (Lyzogubov et al., 2014b). This differed from their previous PEG model, which had injected 1mg PEG to induce CNV in the

mice after 5 days (Lyzogubov et al., 2011). In the modified model, histological evaluation revealed RPE, BM and photoreceptor abnormalities. At 5 days post-injection, apoptosis occurs in the ONL. The pathology observed included thinning of the ONL with a reduced number of nuclei and condensed chromatin, apoptotic bodies in ONL, and shortened PIS/POS suggesting photoreceptor degeneration. The RPE also showed evidence of thinning and was hypopigmented with increased expression of Atg12, indicating increased autophagy. PEG injected mice showed hyperproliferative RPE as well as an increase in the RPE density as a result of undigested POS accumulation and drusen-like deposits was also observed in the sub-RPE space. Thus, this animal shows a phenotype similar to GA. Apart from cellular changes, sub-retinal PEG injection also altered the expression of several risk genes including *C3*, *Mmp9* and *Htra1* in the RPE/choroid, and *C3*, *Cfi*, *serping1* and *lpl* in the retina. However, this model may be less suited to studying BM or choroidal pathology. Studies of retinal function were not carried out in this model.

4.7. *CCL2*^{-/-} /*CX3CR1*^{GFP/GFP} mice

CCL2^{-/-}, *CCR2*^{-/-}, *CX3CR1*^{-/-} single knockout mice and *CCL2*^{-/-} /*CX3CR1*^{-/-} dko mice developed to study the role of retinal microglia and macrophages showed features of AMD from a young age (Ambati et al., 2003; Chan et al., 2008; Combadiere et al., 2007; Luhmann et al., 2013; Tuo et al., 2007). However, the presence of lesions caused by *Crb1* and *rd8* mutation has cast some doubts on the usefulness of these models (Vessey et al., 2012). *CCL2*^{-/-} /*CX3CR1*^{GFP/GFP} mice back-crossed onto a pure C57BL/6J background developed GA-like lesions at 12 months of age, and enhanced pathology was observed following exposure to 800 lux light (Chen et al., 2013). Examination of 12-18 month old *CCL2*^{-/-} /*CX3CR1*^{GFP/GFP} mice revealed progressive yellow/white lesions in the temporal area. However, there was no evidence of CNV in 18 month old transgenic mice with or without chronic light exposure (Chen et al., 2013), suggesting that this model represents a more atrophic phenotype. The atrophic lesions were also pronounced in size and number, following exposure to chronic intense light. RPE flatmounts of 12-18 month old *CCL2*^{-/-} /*CX3CR1*^{GFP/GFP} mice probed with F actin revealed the progressive loss of hexagonal morphology in lesion areas with altered cell junctions. Histological and EM studies showed the RPE in 18 month old *CCL2*^{-/-} /*CX3CR1*^{GFP/GFP} mice to be hypopigmented and vacuolated with an irregular organisation, alongside a

thickened BM. Photoreceptor degeneration as a consequence of RPE dysfunction was observed in 18 month old transgenic mice with reduced cone arrestin and disordered rhodopsin, as well as GABA (marker for amacrine cells) expression. Synaptophysin expression in the ONL also indicated evidence of photoreceptor degeneration. Furthermore, activated Muller glial cells and GFP+ microglial cells were observed in 18 month old CCL2^{-/-}/CX3CR1^{GFP/GFP} mice, which were activated further following exposure to increased light (Chen et al., 2013). Despite some indicators of atrophic AMD, this model failed to develop key features of the disease seen in humans, including wedge-shaped lesion margins and ONL thinning.

4.8. HTRA1 overexpressing mouse model

The Age-Related Maculopathy Susceptibility 2 (*ARMS2*)/Human High Temperature Requirement Serine Protease A1 (*HTRA1*) locus is highly associated with AMD (Abbas and Azzazy, 2013; Ayub et al., 2019; Mohamad et al., 2019). Both fluorescein and indocyanine green angiography in 12 month old HTRA1 transgenic mice show hyperfluorescent lesions with abnormal branching in the fundus. OCT and histology confirm radial branching of choroidal blood vessels, which enter the sub-RPE and retinal space via the BM, indicative of CNV. There is ~ 18% chance of producing a CNV phenotype in these mice. The likelihood of developing CNV was increased further by exposing animals to cigarette smoke (Iejima et al., 2015). Two in ten HTRA1 transgenic mice developed CNV, while one animal developed sub-retinal deposits with vacuolated and hypopigmented RPE (Nakayama et al., 2014). Unlike HTRA1 transgenic mice, ARMS2 transgenic mice do not display any evidence of AMD (Iejima et al., 2015). These findings further support the association of HTRA1 with neovascular AMD. Since only a proportion of HTRA1 transgenic mice develop CNV, the model supports the likelihood that factors such as age and environmental risks also contribute to AMD.

5. Additional models

The following models have distinct mechanisms of action which do not fit into the categories listed above.

5.1. Acute injury GA model

5.1.1. Induced by sodium iodate

An acute injury model of GA was created by sub-retinal delivery of 5mg/ml of sodium iodate (NaIO₃) in Norway rats (Bhutto et al., 2018). Fundoscopy and OCT images taken one-day post-injection revealed acute retinal oedema as well as increased retinal thickness. This initial swelling was followed by a reduction in retinal thickness with the outer retinal layer thinning from day 3 to 7, after which it remained stable until day 28. Furthermore, localised/progressive loss of RPE was observed from 3 days post-injection and a complete loss of RPE was seen by day 7, which persisted up to 28 days post- treatment. Histologically, NaIO₃-injected rats showed well-demarcated RPE atrophy in the injected area as well as a migration of RPE to the sub-retinal space. Reduced thickness of ONL and loss of its photoreceptors was observed on day 3 and continued progressing to day 28. At day 7, further photoreceptor loss was observed, which progressed to a complete loss of the RPE layer, ONL and the external limiting membrane (ELM) by day 28. The INL was in close juxtaposition to the BM in the degenerated area. The choriocapillaris showed evidence of atrophy at day 14 and continued to deteriorate until 28 days post-injection. A glial membrane-like structure was formed by overlapping activated Muller cell processes with vimentin-positive processes in the degenerating photoreceptor area at 7 to 28 days post-injection. The authors reported no evidence of CNV and no functional measurements were carried out. This model could be used to study some features of advanced dry AMD.

5.1.2. Induced by laser

Recently, our group developed a mouse model of GA (Ibbett et al., 2019; Ratnayaka and Lotery, 2020), which is referred to as the Southampton AMD model. Lesions were made using an 810nm laser at a medium power of 32mW to create atrophy of the RPE and the ONL without disrupting the BM. This model avoids the CNV phenotype seen in many other laser-induced models (Lambert et al., 2013). Fundoscopy carried out 1 week post-laser showed a coalescence of atrophic/lasered regions which progresses to form a single well-defined lesion after 2, 4 and 8 weeks. OCT images showed the collapse of ONL and INL, which brought the INL and IPL in close proximity to the BM and RPE/choroid. There was also a decrease in overall retinal thickness at the lesion site, which was due to focal photoreceptor atrophy. ERGs showed a ~23% reduction in A and B waves, indicating a

functional defect of the photoreceptors and reduced signalling to Müller/ON-bipolar cells. Ultrastructurally, the lasered eye showed complete photoreceptor loss with an intact RPE/BM at 12 weeks post laser treatment. The RPE showed both hypo and hyperpigmentation as well as evidence of disorganisation and diminished RPE microvilli. These changes were most prominent within the lesion area. Other changes included evidence of increased astrocyte and microglial activation. The extent of pathology diminished away from the lesion site in a graded manner, consistent with histopathological changes reported by Sarks and colleagues in donor GA tissues (Sarks et al., 1988; Sarks, 1976). The mRNA expression further confirmed elevated inflammatory responses in lasered eyes at 4 weeks post-treatment, with significantly increased levels of C3, GFAP, FcγRI and inflammasome related genes (casp1, cas-8, IL-1β, IL-18). Absence of leakage using FA, as well as the absence of VEGF mRNA and protein expression, revealed salient features of GA with no evidence of choroidal involvement. Therefore, our model may be suitable to investigate GA features, neuroinflammation and genetic susceptibility (Ratnayaka and Lotery, 2020). This model could also be useful for evaluating various immunotherapy treatments for GA.

5.2. Aryl hydrocarbon receptor deficiency mouse model

Aryl hydrocarbon (AhR) is a nuclear receptor, and its activation regulates cellular responses to ultraviolet and blue light as well as the elimination of cellular metabolic waste, especially in counteracting age-related damage (Ma, 2011). Haplotype analysis in AMD patients vs age-matched healthy controls suggests that AhR has a minor association with AMD (Esfandiary et al., 2005). High levels of AhR protein were reported in healthy human donor eyes, which decreased with age (Dwyer et al., 2011). AhR is expressed in the retina and RPE. To better understand the role of AhR in the retina, AhR^{-/-} mice were created by deletion of exon 2 of the AhR gene in C57BL/6J mice (Hu et al., 2013). Fundus and OCT images showed choroidal thinning or atrophy. Functional evaluation of 11 month old AhR^{-/-} mice showed a 50% decrease in B waves with no noticeable change in A waves compare to WT littermates. Histologically, thinning of the INL and ONL was observed, with no changes in PIS or POS at 11 and 16 months. Compared to WT controls, RPE cells in 11 month old AhR^{-/-} mice showed an increase in lipofuscin with a 70% elevation in autofluorescence. These findings indicate a

key role for this receptor in controlling metabolic waste in tissues of the outer retina. The RPE cells also displayed multi-nucleation, hyper/hypopigmentation with vacuolisation and sub-RPE deposits by 11 months. This progressed to pronounced RPE vacuolisation and atrophy at 16 months. BlinD in the BM as well as a thickened BM was also observed, whilst the choroid showed evidence of thinning and atrophy without neovascularisation in 11 month old AhR^{-/-} mice. Thus, this model represents an early AMD phenotype. A second AhR^{-/-} model was created by deletion of exon 1 on the C57BL/6N background, which also displayed an atrophic phenotype. Fundus images of these animals showed the development of whitish spots at 3 months, which progressed to patches of RPE atrophy by 12 months. OCT images in 12 month old AhR^{-/-} mice showed evidence of PIS/POS defects, including the presence of hyper-reflective areas in the photoreceptor-RPE interface. These mice also displayed increased autofluorescence and vacuolisation in RPE, with sub-retinal accumulation of microglia above degenerated RPE, as well as choroidal thinning. Activation of the complement pathway was indicated by the presence of CFH deposits in the sub-retinal space of atrophic regions (Kim et al., 2014).

5.3. 5xFAD mice

The 5xFAD model was developed to study Alzheimer's disease (AD) with a focus on amyloid beta pathology in the brain. The 5xFAD mice express 5 mutations in two genes (APP and Presenilin-1) related to AD (Oakley et al., 2006). AD has been reportedly linked with visual impairment, which suggests that this model might be useful in the investigation of AMD pathology (Criscuolo et al., 2018; Ratnayaka, 2016). The 5xFAD mice revealed a phenotype recapitulating salient features of early AMD. Impairment of the blood-retinal barrier was confirmed, with reduced and irregular ZO1 expression in RPE cells of 12 month old 5xFAD mice compared to WT littermates. Increased amyloid-beta deposits were found in the basal layer of the RPE, similar to those reported in donor human AMD tissues (Dentchev et al., 2003; Lynn et al., 2017; Ratnayaka et al., 2015). Ultrastructurally, RPE displayed loss of apical microvilli as well as increased lipofuscin in the cytoplasm. Age-dependent thickening of the BM with BLamD and BlinD was reported, but no distinct drusen-like deposits were observed by 12 months in 5xFAD mice. The choroidal vasculature demonstrated reduced

fenestration (Park et al., 2017). The limitations of this model include the absence of any focal geographic atrophy or pathology in the POS/PIS and ONL layers.

5.4. *Col18a1*^{-/-} mice

Col18a1 is a heparan **sulfate** proteoglycan which is present in the basement membranes of most epithelial and endothelial cells. Col18a1/endostatin is reported to be present in the basal lamina of RPE, the basement membrane of BM and in the larger vessels of the choroid in aged and AMD donor eyes (Bhutto et al., 2004). Col18a1/endostatin is involved in regulating angiogenesis (Marneros and Olsen, 2005). ERG measurements of Col18a1^{-/-} mice at 2 and 16 months showed reduced and progressive A and B waves confirming impaired photoreceptor function, which worsens over time. Altered vitamin A metabolism reportedly led to a reduction in retinal esters and rhodopsin in 16 month old Col18a1^{-/-} mice compared to WT control, which may explain the observed photoreceptor pathology. EM studies of the RPE in 16 month old Col18a1^{-/-} mice showed minor abnormalities such as disorganised POS and a decrease in interactions with the apical RPE microvilli. The RPE contained electron-dense material with membranous debris as well as sub-RPE deposits. Age-dependent enlargement in sub-retinal deposits was observed in 22 month old Col18a1^{-/-} mice compared to age matched WT controls. The RPE is damaged above these pathogenic deposits, which was confirmed by expression of low RPE65 protein levels in 16 month old mice retinal lysates. Col18a1^{-/-} mice also show increased ubiquitin expression in the basal side of RPE cells. RPE degeneration and age-dependent progressive sub-RPE deposition with RPE cell death were evident in 18 month old Col18a1^{-/-} mice (Marneros et al., 2004). P62/sqstm1 and beclin 1 were also increased in the knockout mice (Kivinen et al., 2016), suggesting impaired autophagy. In 16 month old Col18a1^{-/-} mice, increased GFAP and F4/80 immunoreactivity in the ganglion cell layer and in the retinal/vitreous junction, respectively, confirmed the recruitment of immune cells to the damaged area. Despite these features, this model fails to demonstrate any BM thickening or choroidal abnormalities.

6. Conclusion

As the prevalence of AMD increases there is a growing need for disease-modifying treatments, which require a detailed understanding of complex disease mechanisms.

Although *in vitro* assays have been developed to study retinal, RPE/BM and choroidal function, it is challenging to model the complex multi-layered retina, and its associated tissues, in a dish and translate these discoveries to humans. Rodents share their overall retinal structure and close genetic make-up with humans. Hence, numerous rodent models of AMD have been developed, which recapitulate features of the disease that represent an attractive tool for mechanistic studies as well as drug discovery. Unfortunately, most AMD-like models recapitulate only limited features of the disease. The development of some pathogenic features, which are inconsistent with human AMD pathology, have hampered the full use of rodent models. Recent advances in genetic manipulation and in developmental biology have resulted in the creation of new knock-in or knock out models. The use of non-invasive retinal assessments including fundoscopy, OCT, scanning laser ophthalmoscopy and functional studies with ERG, has added significant value allowing in-depth longitudinal studies using fewer animals. This has also made a positive impact on the 3Rs of replacement, reduction and refinement of animals in experimentation. The use of rodent models allows the manipulation of known AMD risk factors and mechanisms such as complement activation, chemokine/cytokine signalling, oxidative stress and hypoxia amongst others. The development of pharmacological or toxic intervention models using refined doses (PEG mouse model for instance) or chemicals (NaIO₃ model) also recapitulate important features of the disease. Of the recent models reviewed, the Nrf2^{-/-} (Zhao et al., 2011) and CD46^{-/-} models (Lyzogubov et al., 2016) are suitable to study early AMD phenotypes (Figure 2). Both models display important features of early retinal degeneration seen in humans, such as reduced photoreceptor function, shortened photoreceptor IS as well as increased autofluorescence, activation of autophagy, vacuolisation, hypo/hyperpigmentation in the RPE and electron-dense sub-RPE deposits including thickening of the BM and the loss of choroidal fenestrations. However, to study focal atrophic lesions, the intermediate-advanced GA model (Ibbett et al., 2019) (Ratnayaka and Lotery, 2020) and the NaIO₃ (Bhutto et al., 2018) AMD-like model may act as useful tools. Most of the models reviewed here include age as a risk factor in the development of AMD, but increasing evidence suggests a key role for environmental risk factors in driving disease onset/ or progression. For example, older Nrf2^{-/-}, PGC1α^{+/-} mice combined with high glycaemic diet results in late AMD features, while aged human CFH H402 mice on a high fat,

cholesterol-rich diet is be a better model to investigate the early AMD phenotypes. Thus, whilst combining genetic and environmental risk factors are likely to generate more realistic and nuanced models recapitulating specific disease stages, the optimal rodent model differs depending on which stage or type of AMD disease one wants to model. No single rodent model of AMD displays the entirety of AMD phenotypic characteristics.

Acknowledgement

This work was supported by the Gift of Sight Appeal and a NIHR senior investigator award to AL.

Declarations of interest: none

Figure 1. A schematic diagram featuring the stages of age-related macular degeneration (AMD) with its associated risk factors. The figure illustrates the underlying pathological mechanisms, which include: 1) oxidative stress by lipid peroxidation and phagocytosis by the RPE; 2) inflammation via drusenoid deposits; 3) hypoxia by a limited nutrient supply from the choroid due to a thickened BM and neovascularization. The presence of drusen in early AMD recruits activated microglial cells which have migrated from retinal endothelial cells. The drusen serve as the substratum for inflammation. Geographic atrophy (GA) develops when the RPE and photoreceptor cells have degenerated. In neovascular AMD, pathological new blood vessels from the choroid breakthrough the BM and enter the sub-RPE space. This is associated with subretinal fluid accumulation, the recruitment of macrophages from the choriocapillaris as well as activation of microglial cells.

Figure 2: Schematic illustration showing AMD features corresponding to the appropriate rodent model. Rodents lacking a specific disease phenotype(s) are indicated in red text.

References

Abbas, R.O., Azzazy, H.M., 2013. Association of Single Nucleotide Polymorphisms in CFH, ARMS2 and HTRA1 Genes with Risk of Age-related Macular Degeneration in Egyptian Patients. *Ophthalmic genetics*.

Age-Related Eye Disease Study Research, G., 2001. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. *Archives of Ophthalmology* 119, 1439-1452.

Ambati, J., Anand, A., Fernandez, S., Sakurai, E., Lynn, B.C., Kuziel, W.A., Rollins, B.J., Ambati, B.K., 2003. An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. *Nature medicine* 9, 1390-1397.

Anastasopoulos, E., Kakoulidou, A., Coleman, A.L., Sinsheimer, J.S., Wilson, M.R., Yu, F., Salonikiou, A., Koskosas, A., Pappas, T., Founti, P., Lambropoulos, A., Topouzis, F., 2012. Association of sequence variation in the CX3CR1 gene with geographic atrophy age-related macular degeneration in a Greek population. *Current eye research* 37, 1148-1155.

Arjamaa, O., Nikinmaa, M., Salminen, A., Kaarniranta, K., 2009. Regulatory role of HIF-1 α in the pathogenesis of age-related macular degeneration (AMD). *Ageing Res Rev* 8, 349-358.

Ayub, H., Shafique, S., Azam, A., Muslim, I., Qazi, N.A., Akhtar, F., Khan, M.A., Ayub, A., Bashir, S., Bakker, B., Ahmed, S., Azam, M., den Hollander, A.I., Qamar, R., 2019. Association of rs10490924 in ARMS2/HTRA1 with age-related macular degeneration in the Pakistani population. *Ann Hum Genet* 83, 285-290.

Beatty, S., Koh, H., Phil, M., Henson, D., Boulton, M., 2000. The role of oxidative stress in the pathogenesis of age-related macular degeneration. *Survey of ophthalmology* 45, 115-134.

Bhutto, I.A., Kim, S.Y., McLeod, D.S., Merges, C., Fukai, N., Olsen, B.R., Luty, G.A., 2004. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human

control eyes and eyes with age-related macular degeneration. *Invest Ophthalmol Vis Sci* 45, 1544-1552.

Bhutto, I.A., Ogura, S., Baldeosingh, R., McLeod, D.S., Luty, G.A., Edwards, M.M., 2018. An Acute Injury Model for the Phenotypic Characteristics of Geographic Atrophy. *Investigative ophthalmology & visual science* 59, AMD143-AMD151.

Bird, A.C., Phillips, R.L., Hageman, G.S., 2014. Geographic atrophy: a histopathological assessment. *JAMA Ophthalmol* 132, 338-345.

Bishop-Bailey, D., 2008. A Role for PPARbeta/delta in Ocular Angiogenesis. *PPAR Res* 2008, 825970.

Bishop-Bailey, D., Bystrom, J., 2009. Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation. *Pharmacol Ther* 124, 141-150.

Biswal, M.R., Ildefonso, C.J., Mao, H., Seo, S.J., Wang, Z., Li, H., Le, Y.Z., Lewin, A.S., 2016. Conditional Induction of Oxidative Stress in RPE: A Mouse Model of Progressive Retinal Degeneration. *Advances in Experimental Medicine and Biology* 854, 31-37.

Cackett, P., Wong, T.Y., Aung, T., Saw, S.M., Tay, W.T., Rochtchina, E., Mitchell, P., Wang, J.J., 2008. Smoking, cardiovascular risk factors, and age-related macular degeneration in Asians: the Singapore Malay Eye Study. *American Journal of Ophthalmology* 146, 960-967.e961.

Caprara, C., Grimm, C., 2012. From oxygen to erythropoietin: relevance of hypoxia for retinal development, health and disease. *Prog Retin Eye Res* 31, 89-119.

Chakravarthy, U., Wong, T.Y., Fletcher, A., Piau, E., Evans, C., Zlateva, G., Buggage, R., Pleil, A., Mitchell, P., 2010. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. *BMC ophthalmology* 10, 31-2415-2410-2431.

Chan, C.C., Ross, R.J., Shen, D., Ding, X., Majumdar, Z., Bojanowski, C.M., Zhou, M., Salem, N., Jr., Bonner, R., Tuo, J., 2008. Ccl2/Cx3cr1-deficient mice: an animal model for age-related macular degeneration. *Ophthalmic research* 40, 124-128.

Chen, H., Liu, B., Lukas, T.J., Neufeld, A.H., 2008. The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration. *PloS one* 3, e2339.

Chen, M., Hombrebueno, J.R., Luo, C., Penalva, R., Zhao, J., Colhoun, L., Pandi, S.P., Forrester, J.V., Xu, H., 2013. Age- and light-dependent development of localised retinal atrophy in CCL2(-/-)CX3CR1(GFP/GFP) mice. *PloS one* 8, e61381.

Chen, M., Xu, H., 2015. Parainflammation, chronic inflammation, and age-related macular degeneration. *Journal of leukocyte biology* 98, 713-725.

Cho, E., Hung, S., Willett, W.C., Spiegelman, D., Rimm, E.B., Seddon, J.M., Colditz, G.A., Hankinson, S.E., 2001. Prospective study of dietary fat and the risk of age-related macular degeneration. *Am J Clin Nutr* 73, 209-218.

Clark, S.J., Perveen, R., Hakobyan, S., Morgan, B.P., Sim, R.B., Bishop, P.N., Day, A.J., 2010. Impaired binding of the age-related macular degeneration-associated complement factor H 402H allotype to Bruch's membrane in human retina. *J Biol Chem* 285, 30192-30202.

Coffey, P.J., Gias, C., McDermott, C.J., Lundh, P., Pickering, M.C., Sethi, C., Bird, A., Fitzke, F.W., Maass, A., Chen, L.L., Holder, G.E., Luthert, P.J., Salt, T.E., Moss, S.E., Greenwood, J., 2007. Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. *Proceedings of the National Academy of Sciences of the United States of America* 104, 16651-16656.

Colijn, J.M., Buitendijk, G.H.S., Prokofyeva, E., Alves, D., Cachulo, M.L., Khawaja, A.P., Cougnard-Gregoire, A., Merle, B.M.J., Korb, C., Erke, M.G., Bron, A., Anastasopoulos, E., Meester-Smoor, M.A., Segato, T., Piermarocchi, S., de Jong, P.T.V.M., Vingerling, J.R.,

Topouzis, F., Creuzot-Garcher, C., Bertelsen, G., Pfeiffer, N., Fletcher, A.E., Foster, P.J., Silva, R., Korobelnik, J.F., Delcourt, C., Klaver, C.C.W., consortium, E.-R., European Eye Epidemiology, c., 2017. Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future. *Ophthalmology* 124, 1753-1763.

Combadiere, C., Feumi, C., Raoul, W., Keller, N., Rodero, M., Pezard, A., Lavalette, S., Houssier, M., Jonet, L., Picard, E., Debre, P., Sirinyan, M., Deterre, P., Ferroukhi, T., Cohen, S.Y., Chauvaud, D., Jeanny, J.C., Chemtob, S., Behar-Cohen, F., Sennlaub, F., 2007. CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration. *The Journal of clinical investigation* 117, 2920-2928.

Criscuolo, C., Cerri, E., Fabiani, C., Capsoni, S., Cattaneo, A., Domenici, L., 2018. The retina as a window to early dysfunctions of Alzheimer's disease following studies with a 5xFAD mouse model. *Neurobiol Aging* 67, 181-188.

Curcio, C.A., Medeiros, N.E., Millican, C.L., 1998. The Alabama Age-Related Macular Degeneration Grading System for donor eyes. *Investigative ophthalmology & visual science* 39, 1085-1096.

Dentchev, T., Milam, A.H., Lee, V.M., Trojanowski, J.Q., Dunaief, J.L., 2003. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. *Mol Vis* 9, 184-190.

Donoso, L.A., Kim, D., Frost, A., Callahan, A., Hageman, G., 2006. The role of inflammation in the pathogenesis of age-related macular degeneration. *Survey of ophthalmology* 51, 137-152.

Dwyer, M.A., Kazmin, D., Hu, P., McDonnell, D.P., Malek, G., 2011. Research Resource: Nuclear Receptor Atlas of Human Retinal Pigment Epithelial Cells: Potential Relevance to Age-Related Macular Degeneration. *Molecular Endocrinology* 25, 360-372.

Ebrahimi, K.B., Fijalkowski, N., Cano, M., Handa, J.T., 2013. Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration. *J Pathol* 229, 729-742.

Edwards, A.O., Ritter, R., 3rd, Abel, K.J., Manning, A., Panhuysen, C., Farrer, L.A., 2005. Complement factor H polymorphism and age-related macular degeneration. *Science (New York, N.Y.)* 308, 421-424.

Ehrlich, R., Harris, A., Kheradiya, N.S., Winston, D.M., Ciulla, T.A., Wirostko, B., 2008. Age-related macular degeneration and the aging eye. *Clinical interventions in aging* 3, 473-482.

Esfandiary, H., Chakravarthy, U., Patterson, C., Young, I., Hughes, A.E., 2005. Association study of detoxification genes in age related macular degeneration. *The British journal of ophthalmology* 89, 470-474.

Feeney-Burns, L., Hilderbrand, E.S., Eldridge, S., 1984. Aging human RPE: morphometric analysis of macular, equatorial, and peripheral cells. *Investigative ophthalmology & visual science* 25, 195-200.

Felszeghy, S., Viiri, J., Paterno, J.J., Hyttinen, J.M.T., Koskela, A., Chen, M., Leinonen, H., Tanila, H., Kivinen, N., Koistinen, A., Toropainen, E., Amadio, M., Smedowski, A., Reinisalo, M., Winiarczyk, M., Mackiewicz, J., Mutikainen, M., Ruotsalainen, A.K., Kettunen, M., Jokivarsi, K., Sinha, D., Kinnunen, K., Petrovski, G., Blasiak, J., Bjørkøy, G., Koskelainen, A., Skottman, H., Urtti, A., Salminen, A., Kannan, R., Ferrington, D.A., Xu, H., Levonen, A.L., Tavi, P., Kauppinen, A., Kaarniranta, K., 2019. Loss of NRF-2 and PGC-1 α genes leads to retinal pigment epithelium damage resembling dry age-related macular degeneration. *Redox Biol* 20, 1-12.

Fine, S.L., Berger, J.W., Maguire, M.G., Ho, A.C., 2000. Age-related macular degeneration. *The New England journal of medicine* 342, 483-492.

Green, W.R., 1999. Histopathology of age-related macular degeneration. *Molecular vision* 5, 27.

Gu, B.J., Baird, P.N., Vessey, K.A., Skarratt, K.K., Fletcher, E.L., Fuller, S.J., Richardson, A.J., Guymer, R.H., Wiley, J.S., 2013. A rare functional haplotype of the P2RX4 and P2RX7 genes leads to loss of innate phagocytosis and confers increased risk of age-related macular degeneration. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 27, 1479-1487.

Guo, X., Dason, E.S., Zanon-Moreno, V., Jiang, Q., Nahirnyj, A., Chan, D., Flanagan, J.G., Sivak, J.M., 2014. PGC-1 α signaling coordinates susceptibility to metabolic and oxidative injury in the inner retina. *Am J Pathol* 184, 1017-1029.

Gupta, N., Brown, K.E., Milam, A.H., 2003. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. *Exp Eye Res* 76, 463-471.

Hageman, G.S., Anderson, D.H., Johnson, L.V., Hancox, L.S., Taiber, A.J., Hardisty, L.I., Hageman, J.L., Stockman, H.A., Borchardt, J.D., Gehrs, K.M., Smith, R.J., Silvestri, G., Russell, S.R., Klaver, C.C., Barbazetto, I., Chang, S., Yannuzzi, L.A., Barile, G.R., Merriam, J.C., Smith, R.T., Olsh, A.K., Bergeron, J., Zernant, J., Merriam, J.E., Gold, B., Dean, M., Allikmets, R., 2005. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. *Proceedings of the National Academy of Sciences of the United States of America* 102, 7227-7232.

Hageman, G.S., Gehrs, K., Johnson, L.V., Anderson, D., 1995. Age-Related Macular Degeneration (AMD), in: Kolb, H., Fernandez, E., Nelson, R. (Eds.), *Webvision: The Organization of the Retina and Visual System*, Salt Lake City (UT).

Haines, J.L., Hauser, M.A., Schmidt, S., Scott, W.K., Olson, L.M., Gallins, P., Spencer, K.L., Kwan, S.Y., Nouredine, M., Gilbert, J.R., Schnetz-Boutaud, N., Agarwal, A., Postel, E.A.,

Pericak-Vance, M.A., 2005. Complement factor H variant increases the risk of age-related macular degeneration. *Science (New York, N.Y.)* 308, 419-421.

Holers, V.M., Kinoshita, T., Molina, H., 1992. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. *Immunol Today* 13, 231-236.

Holz, F.G., Sadda, S.R., Busbee, B., Chew, E.Y., Mitchell, P., Tufail, A., Brittain, C., Ferrara, D., Gray, S., Honigberg, L., Martin, J., Tong, B., Ehrlich, J.S., Bressler, N.M., Chroma, Spectri Study, I., 2018. Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. *JAMA ophthalmology* 136, 666-677.

Hu, P., Herrmann, R., Bednar, A., Saloupis, P., Dwyer, M.A., Yang, P., Qi, X., Thomas, R.S., Jaffe, G.J., Boulton, M.E., McDonnell, D.P., Malek, G., 2013. Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathology. *Proceedings of the National Academy of Sciences of the United States of America* 110, E4069-4078.

Hubschman, J.P., Reddy, S., Schwartz, S.D., 2009. Age-related macular degeneration: current treatments. *Clinical ophthalmology (Auckland, N.Z.)* 3, 155-166.

Iacovelli, J., Rowe, G.C., Khadka, A., Diaz-Aguilar, D., Spencer, C., Arany, Z., Saint-Geniez, M., 2016. PGC-1 α Induces Human RPE Oxidative Metabolism and Antioxidant Capacity. *Invest Ophthalmol Vis Sci* 57, 1038-1051.

Ibbett, P., Goverdhan, S.V., Pipi, E., Chouhan, J.K., Keeling, E., Angus, E.M., Scott, J.A., Gatherer, M., Page, A., Teeling, J.L., Lotery, A.J., Arjuna Ratnayaka, J., 2019. A lasered mouse model of retinal degeneration displays progressive outer retinal pathology providing insights into early geographic atrophy. *Sci Rep* 9, 7475.

Iejima, D., Nakayama, M., Iwata, T., 2015. HTRA1 Overexpression Induces the Exudative Form of Age-related Macular Degeneration. *Journal of stem cells* 10, 193-203.

Imamura, Y., Noda, S., Hashizume, K., Shinoda, K., Yamaguchi, M., Uchiyama, S., Shimizu, T., Mizushima, Y., Shirasawa, T., Tsubota, K., 2006. Drusen, choroidal neovascularization, and retinal pigment epithelium dysfunction in SOD1-deficient mice: a model of age-related macular degeneration. *Proceedings of the National Academy of Sciences of the United States of America* 103, 11282-11287.

Justilien, V., Pang, J.J., Renganathan, K., Zhan, X., Crabb, J.W., Kim, S.R., Sparrow, J.R., Hauswirth, W.W., Lewin, A.S., 2007. SOD2 knockdown mouse model of early AMD. *Investigative ophthalmology & visual science* 48, 4407-4420.

Kaarniranta, K., Kajdanek, J., Morawiec, J., Pawlowska, E., Blasiak, J., 2018. PGC-1 α Protects RPE Cells of the Aging Retina against Oxidative Stress-Induced Degeneration through the Regulation of Senescence and Mitochondrial Quality Control. The Significance for AMD Pathogenesis. *Int J Mol Sci* 19.

Kaneko, H., Dridi, S., Tarallo, V., Gelfand, B.D., Fowler, B.J., Cho, W.G., Kleinman, M.E., Ponicsan, S.L., Hauswirth, W.W., Chiodo, V.A., Kariko, K., Yoo, J.W., Lee, D.K., Hadziahmetovic, M., Song, Y., Misra, S., Chaudhuri, G., Buaas, F.W., Braun, R.E., Hinton, D.R., Zhang, Q., Grossniklaus, H.E., Provis, J.M., Madigan, M.C., Milam, A.H., Justice, N.L., Albuquerque, R.J., Blandford, A.D., Bogdanovich, S., Hirano, Y., Witta, J., Fuchs, E., Littman, D.R., Ambati, B.K., Rudin, C.M., Chong, M.M., Provost, P., Kugel, J.F., Goodrich, J.A., Dunaief, J.L., Baffi, J.Z., Ambati, J., 2011. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. *Nature* 471, 325-330.

Kim, S.Y., Yang, H.J., Chang, Y.S., Kim, J.W., Brooks, M., Chew, E.Y., Wong, W.T., Fariss, R.N., Rachel, R.A., Cogliati, T., Qian, H., Swaroop, A., 2014. Deletion of aryl hydrocarbon receptor AHR in mice leads to subretinal accumulation of microglia and RPE atrophy. *Investigative ophthalmology & visual science* 55, 6031-6040.

Kivinen, N., Felszeghy, S., Kinnunen, A.I., Setälä, N., Aikio, M., Kinnunen, K., Sironen, R., Pihlajaniemi, T., Kauppinen, A., Kaarniranta, K., 2016. Absence of collagen XVIII in mice causes age-related insufficiency in retinal pigment epithelium proteostasis. *Biogerontology* 17, 749-761.

Klein, M.L., Schultz, D.W., Edwards, A., Matise, T.C., Rust, K., Berselli, C.B., Trzupek, K., Weleber, R.G., Ott, J., Wirtz, M.K., Acott, T.S., 1998. Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. *Archives of Ophthalmology* 116, 1082-1088.

Klein, R.J., Zeiss, C., Chew, E.Y., Tsai, J.Y., Sackler, R.S., Haynes, C., Henning, A.K., SanGiovanni, J.P., Mane, S.M., Mayne, S.T., Bracken, M.B., Ferris, F.L., Ott, J., Barnstable, C., Hoh, J., 2005. Complement factor H polymorphism in age-related macular degeneration. *Science (New York, N.Y.)* 308, 385-389.

Koivunen, P., Tiainen, P., Hyvarinen, J., Williams, K.E., Sormunen, R., Klaus, S.J., Kivirikko, K.I., Myllyharju, J., 2007. An endoplasmic reticulum transmembrane prolyl 4-hydroxylase is induced by hypoxia and acts on hypoxia-inducible factor alpha. *J Biol Chem* 282, 30544-30552.

Laine, M., Jarva, H., Seitsonen, S., Haapasalo, K., Lehtinen, M.J., Lindeman, N., Anderson, D.H., Johnson, P.T., Järvelä, I., Jokiranta, T.S., Hageman, G.S., Immonen, I., Meri, S., 2007. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. *J Immunol* 178, 3831-3836.

Lambert, V., Lecomte, J., Hansen, S., Blacher, S., Gonzalez, M.L., Struman, I., Sounni, N.E., Rozet, E., de Tullio, P., Foidart, J.M., Rakic, J.M., Noel, A., 2013. Laser-induced choroidal neovascularization model to study age-related macular degeneration in mice. *Nat Protoc* 8, 2197-2211.

Landowski, M., Kelly, U., Klingeborn, M., Groelle, M., Ding, J.D., Grigsby, D., Bowes Rickman, C., 2019. Human complement factor H Y402H polymorphism causes an age-related macular

degeneration phenotype and lipoprotein dysregulation in mice. *Proc Natl Acad Sci U S A* 116, 3703-3711.

Leinonen, H., Rossi, M., Salo, A.M., Tiainen, P., Hyvarinen, J., Pitkanen, M., Sormunen, R., Miinalainen, I., Zhang, C., Soininen, R., Kivirikko, K.I., Koskelainen, A., Tanila, H., Myllyharju, J., Koivunen, P., 2016. Lack of P4H-TM in mice results in age-related retinal and renal alterations. *Human molecular genetics* 25, 3810-3823.

Li, H., Chintalapudi, S.R., Jablonski, M.M., 2017. Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development. *Expert opinion on investigational drugs* 26, 1103-1114.

Li, M., Huisinigh, C., Messinger, J., Dolz-Marco, R., Ferrara, D., Freund, K.B., Curcio, C.A., 2018. HISTOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A Multilayer Approach. *Retina* 38, 1937-1953.

Linsenmeier, R.A., Padnick-Silver, L., 2000. Metabolic dependence of photoreceptors on the choroid in the normal and detached retina. *Invest Ophthalmol Vis Sci* 41, 3117-3123.

Liszewski, M.K., Kemper, C., Price, J.D., Atkinson, J.P., 2005. Emerging roles and new functions of CD46. *Springer seminars in immunopathology* 27, 345-358.

Liszewski, M.K., Leung, M., Cui, W., Subramanian, V.B., Parkinson, J., Barlow, P.N., Manchester, M., Atkinson, J.P., 2000. Dissecting sites important for complement regulatory activity in membrane cofactor protein (MCP; CD46). *The Journal of biological chemistry* 275, 37692-37701.

Luhmann, U.F., Carvalho, L.S., Robbie, S.J., Cowing, J.A., Duran, Y., Munro, P.M., Bainbridge, J.W., Ali, R.R., 2013. Ccl2, Cx3cr1 and Ccl2/Cx3cr1 chemokine deficiencies are not sufficient to cause age-related retinal degeneration. *Experimental eye research* 107, 80-87.

Lynn, S.A., Keeling, E., Munday, R., Gabha, G., Griffiths, H., Lotery, A.J., Ratnayaka, J.A., 2017. The complexities underlying age-related macular degeneration: could amyloid beta play an important role? *Neural Regen Res* 12, 538-548.

Lyzogubov, V., Wu, X., Jha, P., Tytarenko, R., Triebwasser, M., Kolar, G., Bertram, P., Bora, P.S., Atkinson, J.P., Bora, N.S., 2014a. Complement regulatory protein CD46 protects against choroidal neovascularization in mice. *The American journal of pathology* 184, 2537-2548.

Lyzogubov, V.V., Bora, N.S., Tytarenko, R.G., Bora, P.S., 2014b. Polyethylene glycol induced mouse model of retinal degeneration. *Experimental eye research* 127, 143-152.

Lyzogubov, V.V., Bora, P.S., Wu, X., Horn, L.E., de Roque, R., Rudolf, X.V., Atkinson, J.P., Bora, N.S., 2016. The Complement Regulatory Protein CD46 Deficient Mouse Spontaneously Develops Dry-Type Age-Related Macular Degeneration-Like Phenotype. *The American journal of pathology* 186, 2088-2104.

Lyzogubov, V.V., Tytarenko, R.G., Liu, J., Bora, N.S., Bora, P.S., 2011. Polyethylene glycol (PEG)-induced mouse model of choroidal neovascularization. *The Journal of biological chemistry* 286, 16229-16237.

Ma, Q., 2011. Influence of light on aryl hydrocarbon receptor signaling and consequences in drug metabolism, physiology and disease. *Expert Opin Drug Metab Toxicol* 7, 1267-1293.

Ma, W., Zhao, L., Wong, W.T., 2012. Microglia in the outer retina and their relevance to pathogenesis of age-related macular degeneration. *Advances in experimental medicine and biology* 723, 37-42.

Malek, G., 2014. Nuclear receptors as potential therapeutic targets for age-related macular degeneration. *Adv Exp Med Biol* 801, 317-321.

Mao, H., Seo, S.J., Biswal, M.R., Li, H., Connors, M., Nandyala, A., Jones, K., Le, Y.Z., Lewin, A.S., 2014. Mitochondrial oxidative stress in the retinal pigment epithelium leads to localized retinal degeneration. *Investigative ophthalmology & visual science* 55, 4613-4627.

Mares-Perlman, J.A., Brady, W.E., Klein, R., VandenLangenberg, G.M., Klein, B.E., Palta, M., 1995. Dietary fat and age-related maculopathy. *Arch Ophthalmol* 113, 743-748.

Marneros, A.G., Keene, D.R., Hansen, U., Fukai, N., Moulton, K., Goletz, P.L., Moiseyev, G., Pawlyk, B.S., Halfter, W., Dong, S., Shibata, M., Li, T., Crouch, R.K., Bruckner, P., Olsen, B.R., 2004. Collagen XVIII/endostatin is essential for vision and retinal pigment epithelial function. *Embo j* 23, 89-99.

Marneros, A.G., Olsen, B.R., 2005. Physiological role of collagen XVIII and endostatin. *Faseb j* 19, 716-728.

Mitchell, P., Wang, J.J., Smith, W., Leeder, S.R., 2002. Smoking and the 5-year incidence of age-related maculopathy: the Blue Mountains Eye Study. *Archives of Ophthalmology* 120, 1357-1363.

Moein Moghimi, S., Hamad, I., Bunger, R., Andresen, T.L., Jorgensen, K., Hunter, A.C., Baranji, L., Rosivall, L., Szebeni, J., 2006. Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. *J Liposome Res* 16, 167-174.

Mohamad, N.A., Ramachandran, V., Mohd Isa, H., Chan, Y.M., Ngah, N.F., Ching, S.M., Hoo, F.K., Wan Sulaiman, W.A., Inche Mat, L.N., Mohamed, M.H., 2019. Association of HTRA1 and ARMS2 gene polymorphisms with response to intravitreal ranibizumab among neovascular age-related macular degenerative subjects. *Hum Genomics* 13, 13.

Monif, M., Burnstock, G., Williams, D.A., 2010. Microglia: proliferation and activation driven by the P2X7 receptor. *The international journal of biochemistry & cell biology* 42, 1753-1756.

Moutray, T., Chakravarthy, U., 2011. Age-related macular degeneration: current treatment and future options. *Therapeutic advances in chronic disease* 2, 325-331.

Mullins, R.F., Russell, S.R., Anderson, D.H., Hageman, G.S., 2000. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 14, 835-846.

Nakayama, M., Iejima, D., Akahori, M., Kamei, J., Goto, A., Iwata, T., 2014. Overexpression of HtrA1 and exposure to mainstream cigarette smoke leads to choroidal neovascularization and subretinal deposits in aged mice. *Investigative ophthalmology & visual science* 55, 6514-6523.

Nowak, J.Z., 2006. Age-related macular degeneration (AMD): pathogenesis and therapy. *Pharmacological reports : PR* 58, 353-363.

Nozaki, M., Raisler, B.J., Sakurai, E., Sarma, J.V., Barnum, S.R., Lambris, J.D., Chen, Y., Zhang, K., Ambati, B.K., Baffi, J.Z., Ambati, J., 2006. Drusen complement components C3a and C5a promote choroidal neovascularization. *Proceedings of the National Academy of Sciences of the United States of America* 103, 2328-2333.

Oakley, H., Cole, S.L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., Berry, R., Vassar, R., 2006. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. *J Neurosci* 26, 10129-10140.

Oehme, F., Ellinghaus, P., Kolkhof, P., Smith, T.J., Ramakrishnan, S., Hutter, J., Schramm, M., Flamme, I., 2002. Overexpression of PH-4, a novel putative proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. *Biochem Biophys Res Commun* 296, 343-349.

Okubo, A., Rosa, R.H., Jr., Bunce, C.V., Alexander, R.A., Fan, J.T., Bird, A.C., Luthert, P.J., 1999. The relationships of age changes in retinal pigment epithelium and Bruch's membrane. *Investigative ophthalmology & visual science* 40, 443-449.

Osterberg, G.A., 1935. *Acta ophthalmologica. Supplementum*, 6, Topography of the layer of rods and cones in the human retina, 13 ed. Copenhagen : [Levin & Munksgaard], pp. 1-103.

Park, S.W., Im, S., Jun, H.O., Lee, K., Park, Y.J., Kim, J.H., Park, W.J., Lee, Y.H., Kim, J.H., 2017. Dry age-related macular degeneration like pathology in aged 5XFAD mice: Ultrastructure and microarray analysis. *Oncotarget* 8, 40006-40018.

Patel, M., Chan, C.C., 2008. Immunopathological aspects of age-related macular degeneration. *Seminars in immunopathology* 30, 97-110.

Pennesi, M.E., Neuringer, M., Courtney, R.J., 2012. Animal models of age related macular degeneration. *Molecular aspects of medicine* 33, 487-509.

Ratnayaka, J.A., & Lynn, S, 2016. Alzheimer's-related amyloid beta peptide aggregates in the ageing retina: implications for sight loss and dementia. *Neuroscience*, 85-108.

Ratnayaka, J.A., Lotery, A.J., 2020. Challenges in studying geographic atrophy (GA) age-related macular degeneration: the potential of a new mouse model with GA-like features. *Neural Regen Res* 15, 863-864.

Ratnayaka, J.A., Serpell, L.C., Lotery, A.J., 2015. Dementia of the eye: the role of amyloid beta in retinal degeneration. *Eye (Lond)* 29, 1013-1026.

Remington, L.A., Goodwin, D., 2011. , *Clinical Anatomy and Physiology of the Visual System*, 3rd Edition ed. Elsevier Health Sciences, pp. 314-315.

Robman, L., Vu, H., Hodge, A., Tikellis, G., Dimitrov, P., McCarty, C., Guymer, R., 2007. Dietary lutein, zeaxanthin, and fats and the progression of age-related macular degeneration. *Can J Ophthalmol* 42, 720-726.

Rohrer, B., Frazer-Abel, A., Leonard, A., Ratnapriya, R., Ward, T., Pietraszkiewicz, A., O'Quinn, E., Adams, K., Swaroop, A., Wolf, B.J., 2019. Association of age-related macular degeneration with complement activation products, smoking, and single nucleotide polymorphisms in South Carolinians of European and African descent. *Mol Vis* 25, 79-92.

Rowan, S., Jiang, S., Korem, T., Szymanski, J., Chang, M.L., Szelog, J., Cassalman, C., Dasuri, K., McGuire, C., Nagai, R., Du, X.L., Brownlee, M., Rabbani, N., Thornalley, P.J., Baleja, J.D., Deik, A.A., Pierce, K.A., Scott, J.M., Clish, C.B., Smith, D.E., Weinberger, A., Avnit-Sagi, T., Lotan-Pompan, M., Segal, E., Taylor, A., 2017. Involvement of a gut-retina axis in protection against dietary glycemia-induced age-related macular degeneration. *Proc Natl Acad Sci U S A* 114, E4472-e4481.

Rowan, S., Weikel, K., Chang, M.L., Nagel, B.A., Thinschmidt, J.S., Carey, A., Grant, M.B., Fliesler, S.J., Smith, D., Taylor, A., 2014. Cfh genotype interacts with dietary glycemic index to modulate age-related macular degeneration-like features in mice. *Invest Ophthalmol Vis Sci* 55, 492-501.

Ryan, S.J., Schachat, A.P., Wilkinson, C.P., Hinton, D.R., Sadda, S.R., Wiedemann, P., 2012. Mechanisms of oxidative stress in retinal injury, in: Ryan, S.J. (Ed.), *Retina*, 5th edition ed. Elsevier's.

Saint-Geniez, M., Jiang, A., Abend, S., Liu, L., Sweigard, H., Connor, K.M., Arany, Z., 2013. PGC-1 α regulates normal and pathological angiogenesis in the retina. *Am J Pathol* 182, 255-265.

Sarks, J.P., Sarks, S.H., Killingsworth, M.C., 1988. Evolution of geographic atrophy of the retinal pigment epithelium. *Eye (Lond)* 2 (Pt 5), 552-577.

Sarks, S.H., 1976. Ageing and degeneration in the macular region: a clinico-pathological study. *The British journal of ophthalmology* 60, 324-341.

Satish, S., Philipose, H., Rosales, M.A.B., Saint-Geniez, M., 2018. Pharmaceutical Induction of PGC-1 α Promotes Retinal Pigment Epithelial Cell Metabolism and Protects against Oxidative Damage. *Oxid Med Cell Longev* 2018, 9248640.

Sheridan, C.M., Pate, S., Hiscott, P., Wong, D., Pattwell, D.M., Kent, D., 2009. Expression of hypoxia-inducible factor-1 α and -2 α in human choroidal neovascular membranes. *Graefes Archive for Clinical and Experimental Ophthalmology* 247, 1361-1367.

Singh, A., Faber, C., Falk, M., Nissen, M.H., Hviid, T.V., Sorensen, T.L., 2012. Altered expression of CD46 and CD59 on leukocytes in neovascular age-related macular degeneration. *American Journal of Ophthalmology* 154, 193-199.e192.

Sinha, D., Valapala, M., Bhutto, I., Patek, B., Zhang, C., Hose, S., Yang, F., Cano, M., Stark, W.J., Luty, G.A., Zigler, J.S., Wawrousek, E.F., 2012. β A3/A1-crystallin is required for proper astrocyte template formation and vascular remodeling in the retina. *Transgenic Res* 21, 1033-1042.

Sridevi Gurubaran, I., Viiri, J., Koskela, A., Hyttinen, J.M.T., Paterno, J.J., Kis, G., Antal, M., Urtti, A., Kauppinen, A., Felszeghy, S., Kaarniranta, K., 2020. Mitophagy in the Retinal Pigment Epithelium of Dry Age-Related Macular Degeneration Investigated in the NFE2L2/PGC-1 α (-/-) Mouse Model. *Int J Mol Sci* 21.

Stefansson, E., Geirsdottir, A., Sigurdsson, H., 2011. Metabolic physiology in age related macular degeneration. *Prog Retin Eye Res* 30, 72-80.

Stuck, M.W., Conley, S.M., Naash, M.I., 2012. Defects in the outer limiting membrane are associated with rosette development in the *Nrl*^{-/-} retina. *PLoS One* 7, e32484.

Sundelin, S., Wihlmark, U., Nilsson, S.E., Brunk, U.T., 1998. Lipofuscin accumulation in cultured retinal pigment epithelial cells reduces their phagocytic capacity. *Current eye research* 17, 851-857.

Tarallo, V., Hirano, Y., Gelfand, B.D., Dridi, S., Kerur, N., Kim, Y., Cho, W.G., Kaneko, H., Fowler, B.J., Bogdanovich, S., Albuquerque, R.J., Hauswirth, W.W., Chiodo, V.A., Kugel, J.F., Goodrich, J.A., Ponicsan, S.L., Chaudhuri, G., Murphy, M.P., Dunaief, J.L., Ambati, B.K., Ogura, Y., Yoo, J.W., Lee, D.K., Provost, P., Hinton, D.R., Nunez, G., Baffi, J.Z., Kleinman, M.E., Ambati, J., 2012. DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. *Cell* 149, 847-859.

Taylor, H.R., Munoz, B., West, S., Bressler, N.M., Bressler, S.B., Rosenthal, F.S., 1990. Visible light and risk of age-related macular degeneration. *Trans Am Ophthalmol Soc* 88, 163-173; discussion 173-168.

Toomey, C.B., Kelly, U., Saban, D.R., Bowes Rickman, C., 2015. Regulation of age-related macular degeneration-like pathology by complement factor H. *Proc Natl Acad Sci U S A* 112, E3040-3049.

Tuo, J., Bojanowski, C.M., Zhou, M., Shen, D., Ross, R.J., Rosenberg, K.I., Cameron, D.J., Yin, C., Kowalak, J.A., Zhuang, Z., Zhang, K., Chan, C.C., 2007. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. *Investigative ophthalmology & visual science* 48, 3827-3836.

Ufret-Vincenty, R.L., Aredo, B., Liu, X., McMahon, A., Chen, P.W., Sun, H., Niederkorn, J.Y., Kedzierski, W., 2010. Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings. *Invest Ophthalmol Vis Sci* 51, 5878-5887.

Valapala, M., Edwards, M., Hose, S., Grebe, R., Bhutto, I.A., Cano, M., Berger, T., Mak, T.W., Wawrousek, E., Handa, J.T., Lutty, G.A., Samuel Zigler, J., Jr., Sinha, D., 2014a. Increased Lipocalin-2 in the retinal pigment epithelium of Cryba1 cKO mice is associated with a chronic inflammatory response. *Aging Cell* 13, 1091-1094.

Valapala, M., Wilson, C., Hose, S., Bhutto, I.A., Grebe, R., Dong, A., Greenbaum, S., Gu, L., Sengupta, S., Cano, M., Hackett, S., Xu, G., Lutty, G.A., Dong, L., Sergeev, Y., Handa, J.T., Campochiaro, P., Wawrousek, E., Zigler, J.S., Jr., Sinha, D., 2014b. Lysosomal-mediated

waste clearance in retinal pigment epithelial cells is regulated by CRYBA1/ β A3/A1-crystallin via V-ATPase-MTORC1 signaling. *Autophagy* 10, 480-496.

Venugopal, R., Jaiswal, A.K., 1998. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes. *Oncogene* 17, 3145-3156.

Vessey, K.A., Greferath, U., Jobling, A.I., Phipps, J.A., Ho, T., Waugh, M., Fletcher, E.L., 2012. Ccl2/Cx3cr1 knockout mice have inner retinal dysfunction but are not an accelerated model of AMD. *Investigative ophthalmology & visual science* 53, 7833-7846.

Vessey, K.A., Gu, B.J., Jobling, A.I., Phipps, J.A., Greferath, U., Tran, M.X., Dixon, M.A., Baird, P.N., Guymer, R.H., Wiley, J.S., Fletcher, E.L., 2017. Loss of Function of P2X7 Receptor Scavenger Activity in Aging Mice: A Novel Model for Investigating the Early Pathogenesis of Age-Related Macular Degeneration. *The American journal of pathology* 187, 1670-1685.

Wang, J.J., Mitchell, P., Smith, W., Cumming, R.G., 1998. Bilateral involvement by age related maculopathy lesions in a population. *British Journal of Ophthalmology* 82, 743-747.

Wang, L., Clark, M.E., Crossman, D.K., Kojima, K., Messinger, J.D., Mobley, J.A., Curcio, C.A., 2010. Abundant lipid and protein components of drusen. *PloS one* 5, e10329.

Wangsa-Wirawan, N.D., Linsenmeier, R.A., 2003. Retinal oxygen: fundamental and clinical aspects. *Arch Ophthalmol* 121, 547-557.

Whitcup, S.M., Sodhi, A., Atkinson, J.P., Holers, V.M., Sinha, D., Rohrer, B., Dick, A.D., 2013. The role of the immune response in age-related macular degeneration. *International journal of inflammation* 2013, 348092.

Wiley, J.S., Gu, B.J., 2012. A new role for the P2X7 receptor: a scavenger receptor for bacteria and apoptotic cells in the absence of serum and extracellular ATP. *Purinergic signalling* 8, 579-586.

Winkler, B.S., Boulton, M.E., Gottsch, J.D., Sternberg, P., 1999. Oxidative damage and age-related macular degeneration. *Molecular vision* 5, 32.

Xu, H., Chen, M., Forrester, J.V., 2009. Para-inflammation in the aging retina. *Progress in retinal and eye research* 28, 348-368.

Yildirim, Z., Ucgun, N.I., Yildirim, F., 2011. The role of oxidative stress and antioxidants in the pathogenesis of age-related macular degeneration. *Clinics (Sao Paulo, Brazil)* 66, 743-746.

Zajac-Pytrus, H.M., Pilecka, A., Turno-Krecicka, A., Adamiec-Mroczek, J., Misiuk-Hojlo, M., 2015. The Dry Form of Age-Related Macular Degeneration (AMD): The Current Concepts of Pathogenesis and Prospects for Treatment. *Advances in clinical and experimental medicine : official organ Wroclaw Medical University* 24, 1099-1104.

Zarbin, M.A., 2004. Current concepts in the pathogenesis of age-related macular degeneration. *Archives of Ophthalmology* 122, 598-614.

Zhang, M., Chu, Y., Mowery, J., Konkeli, B., Galli, S., Theos, A.C., Golestaneh, N., 2018. Pgc-1 α repression and high-fat diet induce age-related macular degeneration-like phenotypes in mice. *Dis Model Mech* 11.


Zhao, Z., Chen, Y., Wang, J., Sternberg, P., Freeman, M.L., Grossniklaus, H.E., Cai, J., 2011. Age-related retinopathy in NRF2-deficient mice. *PloS one* 6, e19456.

Zhao, Z., Xu, P., Jie, Z., Zuo, Y., Yu, B., Soong, L., Sun, J., Chen, Y., Cai, J., 2014. $\gamma\delta$ T cells as a major source of IL-17 production during age-dependent RPE degeneration. *Investigative ophthalmology & visual science* 55, 6580-6589.

Zigler, J.S., Jr., Sinha, D., 2015. β A3/A1-crystallin: more than a lens protein. *Prog Retin Eye Res* 44, 62-85.

Zigler, J.S., Jr., Zhang, C., Grebe, R., Sehrawat, G., Hackler, L., Jr., Adhya, S., Hose, S., McLeod, D.S., Bhutto, I., Barbour, W., Parthasarathy, G., Zack, D.J., Sergeev, Y., Luttly, G.A., Handa,

J.T., Sinha, D., 2011. Mutation in the β A3/A1-crystallin gene impairs phagosome degradation in the retinal pigmented epithelium of the rat. *J Cell Sci* 124, 523-531.






Figure 2: Schematic illustration showing AMD features corresponding to the appropriate rodent model. Rodents lacking a specific disease phenotype(s) are indicated in red text.

Table 1: List of AMD animal model pathology and limitation

	Name	Time	Clinical changes	Functional changes	Histological / Ultrastructural changes	AMD	Limitations	Ref
Oxidative stress models	SOD2^{-/-} Conditional KO mice	6 to 9 months	Fundus - White reflective area OCT - ONL thinning, increased choroidal porosity FA - retinal blood vessel abnormality	ERG - reduced photoreceptor function	Retina - shortened POS and PIS RPE -thickened, vacuolated, increased AF Deposit -BLam like Choroid -no CNV	Late dry	white area in fundoscopy not replicative of atrophy in human eye, unclear pathology of atrophy in histology and OCT	Biswal et al., 2016; Mao et al., 2014
	Nrf2^{-/-} mice	11-18 months	Fundus -yellowish soft drusen like deposit	ERG - reduced photoreceptor function	Retina -POS atrophy RPE -Vacuolated, hyper/hypopigmented, hyperplasia, increased AF, compromised autophagy, infiltrated cells in sub-RPE BM - Thickened Deposit -Continuous basal deposit	Early	few peripheral drusen	Zhao et al., 2011

			Choroid- Lost fenestration, thickened CC endothelium			
			CNV (18%)			
PPARβ/δ^{-/-}	18 months	ERG- reduced B wave	Retina- no change RPE- hypo/hyperpigmentation, damaged basal infolding, increased autofluorescence BM- thickening Deposit- patchy/continuous sub-RPE	Early	No change in retina and choroid	Choudhary, 2016
PGC1α+/- mice	3 months +4 months with HFD		Retina- thinned IS/OS RPE- lipofuscin accumulation, fissured, lost melanosomes, BM- thickening Choroid- lost fenestration Deposit- BLamD	Early	No functional measurement	Zhang et al., 2018
PGC1α/Nrf2 dko	12 months	ERG- reduced photoreceptor function	Retina- focal PR damage, ONL thinning RPE- vacuolated, hypertrophic, damaged autolysosomes, damaged	Early	No information of choroidal abnormalities	Felszeghy et al., 2019

			mitochondria, lost basal folding, increased lipofuscin and melanosomes, increased autofluorescence			Sridevi Gurubaran et al., 2020
			BM -thickening			
			Deposit - drusen like			
Cryba1 cko mice	7-12 months	ERG- reduced photoreceptor function	RPE - lost tight junction and apical villi, lipid accumulation, vacuolated, more melanosomes, reduced lysosome and autophagosomes	Late dry	Absence of BM thickening, ONL thinning and choroidal abnormalities	Valapala et al., 2014b
HFD	12 months +12 month HFD		Retina - thinned, disorganised PR, swelled IS, lost synapsis RPE -vacuolated, hypopigmented, thinned, disorganised, multi-layered, atrophic and increased autofluorescence, lost basal infolding, Increased lipofuscin, phagosomes. Deposit -BLamD, subretinal deposit	Early	No functional or clinical examination	Rowan et al., 2017

Hypoxia targeted model	P4h-Tm^{-/-} mice	10 and 14.5 months	ERG- reduced cone function (5-7 months), reduced rod function (12-13 months)	10 months: RPE- disorder, broadened intercellular space, basal infolding Deposit- BLam like and drusen like 14.5 months: Retina- ONL thinned, shortened PIS/POS, infolding ONL and POS RPE- Thinning, compromised phagocytosis	Early	no clinical examination and unexplained choroidal pathology	Leinonen et al., 2016
Inflammation targeted models	CFH transgenic mice	90 week	ERG- impaired photoreceptor function	RPE- multinucleated Deposit- BLamD	Early	unexplained retinal, BM and choroidal abnormalities	Landowski et al., 2019
	CFH^{+/-} mice with High fat cholesterol (HFC) diet	2 year old	ERG- impaired photoreceptor function	Retina- ONL thinning RPE- multinucleated and hypertrophic, thinned RPE Deposit- larger BLamD	Early	unexplained BM and choroidal abnormalities	
	CFH^{-/-} with low glycemic diet	44 week		RPE- thinned, vacuolated, disorganised, basal folding damage, increased lipofuscin, autophagosomes	Early	No functional measurement and unexplained	Rowan et al., 2014

				BM-thickening		choroidal abnormalities	
				Deposit-BLamD			
CD46^{-/-} mice	12 months			Retina- Photoreceptor apoptosis, reduced nuclear density in ONL, macrophage like cell in subretinal space	Early	no clinical and functional measures	Lyzogubov et al., 2016
				RPE -Hypertrophic, multinucleated, vacuolated, increased AF, activated autophagy			
				BM- Thickened			
				Deposit -Electron dense material			
				Choroid- Thinning, reduced fenestration			
Inflammasome mice			Fundus-GA like	RPE -disturbed cobble stone structure, degenerated	Late dry		Tarallo et al., 2012
P2X7^{-/-} mice	12-18 months	Fundus- whitish lesion spot	ERG -reduced rod photoreceptor function	Retina -Gliosis, reduced retinal microglial phagocytosis	Early	ONL, PIS/POS and choroidal changes was not described	Vessey et al., 2017
				RPE -Hypertrophic, vacuolated, multinucleated, increased lipofuscin and AF			
				BM- Thickened			
				Deposit -BLam like			

				BLin like, electron lucent deposit			
Other models	cc12/cx3cr1 double knockout mice	12 -18 months	Fundus- yellowish/whitish lesion at periphery No CNV	Retina -Photoreceptor degeneration RPE -Hypopigmented vacuolated, irregular organisation BM - Thickened	Late dry	lack of wedge shaped morphology and ONL thinning	Chen et al., 2013
	HTRA1 over expressing mice	12 months	FA and indocyanine green angiography- hyperfluorescent lesion with abnormal branching	Choroid -Radial branching of choroidal blood vessel, subretinal haemorrhage	Late wet	low percent of animals developed disease	Iejima et al. 2015
	PEG induced mice	5 days		Retina -thinned ONL, shortened PIS/POS RPE - Thinning, hypopigmentation, hyperproliferative, increased RPE density, increased autophagy Deposit -Drusen like	dry	no clinical and functional measures, no description about choroid and BM	Lyzogubov V. V. et al., 2014b
	Acute Geographic atrophy rat	7 days	Fundus -retinal thinning OCT -RPE loss	Retina -Complete loss of photoreceptor, RPE, ONL, glial membrane, wedge shaped atrophy RPE -Well demarcated atrophy	Late dry	No functional measurement	Bhutto et al., 2018

Laser induced acute geographic atrophy like mice	2-8 wk	Fundus- whitish lesion spot (retinal thinning) OCT- wedge shaped atrophy FA- absence of choroidal leakage	ERG- reduced photoreceptor function	Retina- Complete photoreceptor loss, ONL absence RPE - Disorganised, hypo/hyperpigmented, reduced apical microvilli	Late dry		Ibbett et al., 2019
AhR^{-/-} mice	11 months	Fundus and OCT- choroidal thinning/atrophy	ERG- reduced B wave	Retina- INL and ONL thinning RPE- Increased lipofuscin and AF, multinucleated, hyper/hypopigmented, vacuolated Deposit- BLinD BM - thickened Choroid- Thinning and atrophy	Early	PIS/POS shortening wasn't shown,	Hu et al., 2013
AhR^{-/-} mice (C57BL/6N)	12 months	Fundus- RPE atrophy OCT- Hyperreflective area		RPE- Increased AF, vacuolated, subretinal microglial accumulation Choroid- Thinned	Late dry	no geographic atrophy like phenotype seen, unexplained POS/PIS and ONL organisation	Kim et al., 2014
5X FAD mice	12 months			RPE- Loss of apical microvilli, increased lipofuscin	Early	No clinical or functional measurement,	Park et al., 2017

				BM- Thickened		unexplained retinal pathology	
				Deposit- BLamD, BLinD			
				Choroid- Reduced fenestration			
Col18a1-/- mice	16 -18 months	ERG- reduced photoreceptor function		Retina- reduced rhodopsin, perfused and non-atrophic	Early	No BM thickening and choroidal abnormalities	Marneros et al., 2004
				RPE- lost apical villi, damaged RPE layer, reduced RPE65, cell death and increased autophagy			Kivinen et al., 2016
				Deposit- sub-RPE			
OCT- optical coherence tomography, FA- fluorescein angiography, ERG- Electroretinography, RPE- retinal pigment epithelium, BM- bruch's membrane, PIS- photoreceptor inner segment, POS- photoreceptor outer segment, ONL- outer nuclear layer, AF- autofluorescence, BLamD- basal laminar deposit, BLinD- basal linear deposit, CC- choriocapillary, CNV- choroidal neovascularisation, HFD- high fat diet							